US20190038623A1 - Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria - Google Patents

Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria Download PDF

Info

Publication number
US20190038623A1
US20190038623A1 US16/053,716 US201816053716A US2019038623A1 US 20190038623 A1 US20190038623 A1 US 20190038623A1 US 201816053716 A US201816053716 A US 201816053716A US 2019038623 A1 US2019038623 A1 US 2019038623A1
Authority
US
United States
Prior art keywords
inhibitor
compound
cfd
subject
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/053,716
Other languages
English (en)
Inventor
Mingjun Huang
Dharaben Patel
Steven D. Podos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achillion Pharmaceuticals Inc
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Priority to US16/053,716 priority Critical patent/US20190038623A1/en
Assigned to ACHILLION PHARMACEUTICALS, INC. reassignment ACHILLION PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HUANG, MINGJUN, PATEL, Dharaben, PODOS, STEVEN D.
Assigned to ACHILLION PHARMACEUTICALS, INC. reassignment ACHILLION PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PATEL, Dharaben, HUANG, MINGJUN, PODOS, STEVEN D.
Publication of US20190038623A1 publication Critical patent/US20190038623A1/en
Priority to US16/700,910 priority patent/US20200101071A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • This invention is in the area of therapeutic regimens for the treatment of the complement-mediated disorder paroxysmal nocturnal hemoglobinuria (PNH).
  • PNH paroxysmal nocturnal hemoglobinuria
  • the complement system is a part of the innate immune system which does not adapt to changes over the course of the host's life, but is recruited and used by the adaptive immune system. For example, it assists, or complements, the ability of antibodies and phagocytic cells to clear pathogens.
  • This sophisticated regulatory pathway allows rapid reaction to pathogenic organisms while protecting host cells from destruction.
  • Over thirty proteins and protein fragments make up the complement system. These proteins act through opsonization (enhancing phagocytosis of antigens), chemotaxis (attracting macrophages and neutrophils), cell lysis (rupturing membranes of foreign cells), and agglutination (clustering and binding of pathogens together).
  • Complement Factor D plays an early and central role in activation of the alternative pathway of the complement cascade. Activation of the alternative complement pathway is initiated by spontaneous hydrolysis of a thioester bond within C3 to produce C3(H 2 O), which associates with Factor B to form the C3(H 2 O)B complex.
  • Complement Factor D acts to cleave Factor B within the C3(H 2 O)B complex to form Ba and Bb. The Bb fragment remains associated with C3(H 2 O) to form the alternative pathway C3 convertase C3(H 2 O)Bb.
  • C3b generated by any of the C3 convertases also associates with Factor B to form C3bB, which Factor D cleaves to generate the later stage alternative pathway C3 convertase C3bBb.
  • This latter form of the alternative pathway C3 convertase may provide important downstream amplification within all three of the defined complement pathways, leading ultimately to the recruitment and assembly of additional factors in the complement cascade pathway, including the cleavage of C5 to C5a and C5b.
  • C5b acts in the assembly of factors C6, C7, C8, and C9 into the membrane attack complex, which can destroy pathogenic cells by lysing the cell.
  • Paroxysmal nocturnal hemoglobinuria is a clonal hematopoietic stem cell (HSC) disease that presents with hemolytic anemia, thrombosis, and smooth muscle dystonia, as well as bone marrow failure in some cases.
  • PNH is caused by somatic mutations in PIGA (which encodes phosphatidylinositol N-acetylglucosaminyltransferase subunit A) in one or more HSC clones.
  • PIGA glycosylphosphatidylinositol
  • GPI-anchored proteins such as complement decay-accelerating factor (also known as CD55) and CD59 glycoprotein (CD59), which are both complement inhibitors.
  • CD55 and CD59 renders PNH erythrocytes susceptible to destructive C3 convertase and terminal complex assembly on their membranes following normal slow AP activation (“tickover”) in the fluid phase, resulting in intravascular hemolysis, which can lead to thrombosis and much of the morbidity and mortality associated with PNH.
  • Eculizumab (SOLARIS, Alexion Pharmaceuticals, Inc.), a monoclonal antibody complement inhibitor, is the only approved therapy for PNH.
  • eculizumab blocks assembly of the hemolytic terminal complex (also known as membrane attack complex, MAC).
  • MAC membrane attack complex
  • C5 blockade by eculizumab prevents complement-mediated intravascular hemolysis in PNH.
  • Eculizumab treatment leads to increased deposition of complement C3 fragments on PNH membranes, which can result in extravascular phagocytic elimination of opsonized erythrocytes in the spleen and the liver (A. M.
  • Suboptimal inhibition of hemolysis remains a major problem in treating PNH. It is an object of the present invention to provide improved methods and treatments which sufficiently inhibit intravascular and extravascular hemolysis of PNH erythrocytes. It is a further object of the present invention to inhibit or reduce the deposition of C3 fragments on PNH erythrocytes. It is further object of the present invention to improve the efficacy of complement inhibitor therapy for the treatment of PNH.
  • kits for treating a subject with PNH comprising administering to a subject a therapeutically effective amount of complement component C5 (C5) inhibitor, complement component C3 (C3) inhibitor, or complement factor B (CFB) inhibitor in combination with a therapeutically effective amount of small molecule complement factor D (CFD) inhibitor.
  • C5 complement component C5
  • C3 complement component C3
  • CFB complement factor B
  • CFD small molecule complement factor D
  • a CFD inhibitor in the therapeutic regimen, prohibition of the upstream C3 convertase assembly and C3 fragment deposition contributing to extravascular hemolysis associated with the clinical use of C5 inhibitors alone, for example eculizumab, is achieved.
  • a CFD inhibitor described herein in combination with, or following administration of, a C3 inhibitor, or a CFB inhibitor, significant improvement in the inhibition of the upstream C3 convertase assembly and C3 fragment deposition contributing to extravascular hemolysis associated with PNH is attained.
  • CFD inhibitor described herein in combination with a C5 inhibitor or C3 inhibitor synergistically enhances inhibition of hemolysis.
  • a CFD inhibitor described herein in a therapeutic protocol, an improved treatment regimen is provided for subjects with PNH who experience incomplete intravascular hemolysis inhibition with a C5 inhibitor or C3 inhibitor treatment alone. Accordingly, the inclusion of a CFD inhibitor described herein in the treatment regimen acts as an effective salvage therapy and drastically extends the therapeutic effectiveness of the C5 and/or C3 inhibitor.
  • CFD inhibitor described herein in combination with a C5 inhibitor synergistically enhances inhibition of hemolysis, including C3-fragment deposition induced hemolysis associated with extravascular hemolysis in PNH, a major complication associated with the clinical use of standard of care C5 inhibitor treatments such as eculizumab.
  • the clinical use of, for example, the C5 inhibitor eculizumab has been associated with the development of extravascular hemolysis through C3-fragment deposition and, in certain subpopulations, an incomplete inhibition of intravascular hemolysis.
  • the use of a CFD inhibitor described herein inhibits the membrane deposition of C3 fragments on PNH erythrocytes.
  • a CFD inhibitor described herein in combination with, for example, eculizumab both MAC assembly and C3 fragment deposition on PNH erythrocytes can be inhibited. Therefore, the combination of a CFD inhibitor described herein and a C5 inhibitor, for example eculizumab, provides an improved therapeutic approach to treat PNH subjects who are suboptimal responders to a C5 inhibitor and/or subject to extravascular hemolysis.
  • a CFD inhibitor described herein reduces the density of deposited C3b clusters, to which C5 binding is thereby more readily inhibited by a C5 inhibitor, for example eculizumab. While eculizumab binds to C5 and blocks the terminal pathway of complement upstream of CD59, it does not address the deposition of C3 fragments as a result of the complement alternative pathway due to the absence of CD55 on PNH erythrocytes. As a result, PNH erythrocytes accumulate C3 fragment and are susceptible to extravascular hemolysis by opsonization. In contrast, inclusion of a CFD inhibitor described herein inhibits both complement terminal pathway activation as well as opsonization, complementing in a synergistic fashion the effects of C5 inhibitors.
  • the present invention provides methods for treating a subject with PNH comprising administering to the subject a therapeutically effective amount of a C5 inhibitor, a C3 inhibitor, a CFB inhibitor or a pan-inhibitor to complement components in combination with a therapeutically effective amount of a CFD inhibitor described herein.
  • a CFD inhibitor of Formula I may be used:
  • composition or a pharmaceutically acceptable salt, N-oxide, isotopic derivative, or prodrug thereof, optionally in a pharmaceutically acceptable carrier to form a composition;
  • X is selected from N and CH;
  • R 1 is selected from hydrogen, C 1 -C 3 alkyl, and halogen
  • R 2 is selected from hydrogen and C 1 -C 3 alkyl
  • R 3 is selected from hydrogen, C 1 -C 3 alkyl, and halogen
  • R 4 is selected from hydrogen, C 1 -C 3 alkyl, and halogen
  • R 5 is selected from hydrogen, C 1 -C 3 alkyl, halogen, and cyano.
  • the compound of Formula I is selected from:
  • a CFD inhibitor of Formula II may be used:
  • composition or a pharmaceutically acceptable salt, N-oxide, isotopic derivative, or prodrug thereof, optionally in a pharmaceutically acceptable carrier to form a composition;
  • X is selected from N and CH;
  • R 1 is selected from hydrogen, C 1 -C 3 alkyl, and halogen
  • R 2 is selected from hydrogen and C 1 -C 3 alkyl
  • R 3 is selected from hydrogen, C 1 -C 3 alkyl, and halogen
  • R 4 is selected from hydrogen, C 1 -C 3 alkyl, and halogen
  • R 5 is selected from hydrogen, C 1 -C 3 alkyl, halogen, and cyano.
  • the compound of Formula II is selected from:
  • a method of treating a subject with PNH comprising administering to the subject a therapeutically effective amount of a C5 inhibitor in combination or alternation with a therapeutically effective amount of a CFD inhibitor selected from Formula I or Formula II, or a pharmaceutically acceptable salt thereof.
  • the C5 inhibitor is a monoclonal antibody to C5.
  • the C5 inhibitor is eculizumab.
  • C5 inhibitors for use in the methods described herein include, but are not limited to: a recombinant human minibody, for example Mubodina® (Adienne Pharma and Biotech); coversin ( Akari Therapeutics); Tesidolumab/LFG316 (Novartis/Morphosys); ARC-1905 (Ophthotech); RA101348 (Ra Pharmaceuticals); RA101495 (Ra Pharmaceuticals); SOBI002 (Swedish Orphan Biovitrum); ARC1005 (Novo Nordisk); a SOMAmer for C5 (SomaLogic); SSL7; MEDI7814 (MedImmune); aurin tricarboxylic acid (Aurin Biotech); an aurin tricarboxylic acid derivative (Aurin Biotech); RG6107/SKY59 (Roche Pharmaceuticals); ALXN1210 (Alexion Pharmaceuticals); ALXN5500 (Alexion Pharmaceuticals); TT30 (Alexion Pharmaceuticals); A
  • the C5 inhibitor is eculizumab
  • the CFD inhibitor is selected from Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
  • the subject has a genetic polymorphism in Complement Receptor 1 gene (CR1).
  • the CR1 polymorphism is HindIII H/L or L/L genotype (see, for example, Rondelli et al., Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria, Haematologica. 2014 February; 99(2): 262-266, incorporated herein by reference).
  • a method of treating a subject with PNH comprising administering to the subject a CFD inhibitor selected from Formula I or Formula II, or a pharmaceutically acceptable salt thereof, wherein the subject at the time of administration of the CFD inhibitor has been or is currently receiving a therapeutic regimen comprising the administration of a C5 inhibitor and is experiencing extravascular hemolysis or residual intravascular hemolysis.
  • Subjects receiving a C5 inhibitor who develop extravascular hemolysis may remain or become anemic, that is, have a hemoglobin level of less than about 12 g/dL, and more particularly less than about 10 g/dL, while maintaining, for example, normalized or slightly elevated lactate dehydrogenase (LDH) levels, for example LDH levels of less than about 250 U/L.
  • LDH lactate dehydrogenase
  • subjects receiving a C5 inhibitor suffering from incomplete inhibition or residual intravascular hemolysis remain anemic, and may also have elevated LDH levels, for example an LDH levels 1.0 ⁇ upper limit of normal (ULN) or greater.
  • the C5 inhibitor upon administration of the CFD inhibitor, the C5 inhibitor also continues to be administered.
  • the C5 inhibitor upon administration of the CFD inhibitor, the C5 inhibitor is no longer administered.
  • the C5 inhibitor is a monoclonal antibody to C5.
  • the C5 inhibitor is eculizumab
  • the CFD inhibitor is selected from Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
  • the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor.
  • a method of treating a subject with PNH comprising administering to the subject an effective amount of a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically acceptable salt therein, wherein, at the time of the administration of the CFD inhibitor, the subject has been or is currently receiving a therapeutic regimen comprising the administration of a C5 inhibitor, and wherein the subject has a Hgb level of less than about 12 g/dL. In one embodiment, the subject has a Hgb of less than about 10 g/dL. In one embodiment, the subject has a Hgb of less than about 8 g/dL. In one embodiment, at the time of administration of the CFD inhibitor, the subject is blood transfusion dependent.
  • the subject at the time of administration of the CFD inhibitor, has received one or more blood transfusions within the prior twelve months. In one embodiment, the subject has received two or more blood transfusions with in the prior six months. In one embodiment, the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor. In a particular embodiment, upon administration of the CFD inhibitor, the C5 inhibitor also continues to be administered. In an alternative embodiment, upon administration of the CFD inhibitor, the C5 inhibitor is no longer administered. In a particular embodiment, the C5 inhibitor is a monoclonal antibody to C5.
  • the C5 inhibitor is eculizumab
  • the CFD inhibitor is selected from Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
  • the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor.
  • a method of treating a subject with PNH comprising administering to the subject an effective amount of a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically acceptable salt therein, wherein, at the time of the administration of the CFD inhibitor, the subject has been or is currently receiving a therapeutic regimen comprising the administration of a C5 inhibitor, and wherein the subject has a Hgb level of less than about 12 g/dL and an LDH level greater than 1.0 ⁇ ULN.
  • the subject has a Hgb of less than about 10 g/dL.
  • the subject has a Hgb of less than about 8 g/dL.
  • the subject has an LDH level greater than 1.0 ⁇ ULN.
  • the subject at the time of administration of the CFD inhibitor, has received one or more blood transfusions within the prior twelve months. In one embodiment, the subject has received two or more blood transfusions with in the prior six months.
  • the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor.
  • the C5 inhibitor upon administration of the CFD inhibitor, the C5 inhibitor also continues to be administered.
  • the C5 inhibitor upon administration of the CFD inhibitor, the C5 inhibitor is no longer administered.
  • the C5 inhibitor is a monoclonal antibody to C5.
  • the C5 inhibitor is eculizumab
  • the CFD inhibitor is selected from Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
  • the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor.
  • a method of treating a subject with PNH comprising administering to the subject an effective amount of a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically acceptable salt therein, wherein, at the time of the administration of the CFD inhibitor, the subject has been or is currently receiving a therapeutic regimen comprising the administration of a C5 inhibitor, and wherein the subject has a Hgb level of less than about 12 g/dL and an LDH level less than about 0.25 ⁇ ULN.
  • the subject has a Hgb of less than about 10 g/dL.
  • the subject has a Hgb of less than about 8 g/dL.
  • the subject has an LDH level within a normal range.
  • the subject at the time of administration of the CFD inhibitor, has received one or more blood transfusions within the prior twelve months. In one embodiment, the subject has received two or more blood transfusions with in the prior six months.
  • the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor.
  • the C5 inhibitor upon administration of the CFD inhibitor, the C5 inhibitor also continues to be administered.
  • the C5 inhibitor upon administration of the CFD inhibitor, the C5 inhibitor is no longer administered.
  • the C5 inhibitor is a monoclonal antibody to C5.
  • the C5 inhibitor is eculizumab
  • the CFD inhibitor is selected from Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
  • the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor.
  • Also provided herein is a method of treating a subject with PNH comprising administering to the subject a therapeutically effective amount of a CFD inhibitor selected from Formula I or Formula II in combination with a C3 inhibitor.
  • a CFD inhibitor selected from Formula I or Formula II in combination with a complement component C3 inhibitor also provides for synergistic inhibition of hemolysis of PNH erythrocytes. These synergistic effects provide for increased therapeutic efficacy in the treatment of PNH, while reducing the required amount of inhibitor necessary for therapeutic efficacy.
  • the C3 inhibitor is selected from compstatin or a compstatin analog or derivative.
  • the C3 inhibitor is compstatin.
  • the C3 inhibitor is the compstatin analog 4(1MeW)/APL-1. In a particular embodiment, the C3 inhibitor is the compstatin analog CP-40/AMY-101. In a particular embodiment, the C3 inhibitor is the compstatin analog Peg-CP-40. 4(1MeW)/APL-1, CP40/AMY-101, and Peg-CP-40 are described in Risitano, Ricklin et al., Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria, Blood. 2014 Mar. 27; 123(13):2094-101, incorporated herein by reference.
  • the C3 inhibitor is AMY-201 (Amyndas Pharmaceuticals). In a particular embodiment, the C3 inhibitor is APL-2 (Apellis Pharmaceuticals). In a particular embodiment, the C3 inhibitor is ATA (aurin tricarboxylic acid) (Aurin Biotech, US Pat Appl Pub US20130035392, incorporated herein by reference). In one embodiment, the CFD inhibitor is selected from Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
  • a method of treating a subject with PNH comprising administering to the subject a therapeutically effective amount of a CFD inhibitor selected from Formula I or Formula II in combination with a complement factor B inhibitor.
  • a CFD inhibitor selected from a compound of Formula I or Formula II in combination with a factor B inhibitor provides for improved inhibition of hemolysis of PNH erythrocytes, allowing for increased therapeutic efficacy in the treatment of PNH, while reducing the required amount of inhibitor necessary for therapeutic efficacy.
  • the CFB inhibitor is LNP023 (Novartis).
  • the CFB inhibitor is selected from an inhibitor described in WO2013/192345, incorporated by reference herein.
  • the CFB inhibitor is
  • the CFB inhibitor is selected from an inhibitor described in International Application No. PCT/US17/39587, incorporated herein by reference.
  • the CFD inhibitor is selected from Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
  • a method of treating a subject with PNH comprising administering to the subject a therapeutically effective amount of a CFD inhibitor selected from Formula I or Formula II in combination with a pan-inhibitor to complement components.
  • the inhibitor is FUT-175.
  • the CFD inhibitor is selected from Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
  • a pharmaceutically acceptable combination or composition as described herein comprising a CFD inhibitor selected from Formula I or Formula II or its pharmaceutically acceptable salt and a C3 or C5 inhibitor.
  • the CFD inhibitor is selected from Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
  • a pharmaceutically acceptable combination or composition as described herein comprising a CFD inhibitor of Formula I or Formula II or its pharmaceutically acceptable salt and a CFB inhibitor.
  • the CFB inhibitor is a compound as described in PCT/US17/39587, incorporated herein by references.
  • the CFB inhibitor is:
  • the CFD inhibitor is selected from Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
  • the present invention provides a pharmaceutically acceptable combination or composition as described herein, comprising a CFD inhibitor of Formula I or Formula II or its pharmaceutically acceptable salt and a pan-inhibitor to complement components.
  • the pan-inhibitor is FUT-175.
  • the CFD inhibitor is selected from Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
  • FIGS. 1A-1B are three-dimensional surface graphs showing that the combination of Compound 1 and eculizumab synergistically inhibit complement-mediated hemolysis of PNH erythrocytes.
  • Each of the surface graphs have distinct and consistent positive peaks and as described in Example 1, substantial synergy volume.
  • the concentration of eculizumab ( ⁇ g/mL) is measured on the x-axis and the concentration of Compound 1 ( ⁇ M) is measured on the y-axis.
  • the z-axis represents the difference between measured inhibition and a theoretically determined additive inhibition.
  • the positive surface peaks indicate greater inhibition than expected and therefore synergy, while negative surface peaks indicate less inhibition than expected and therefore antagonism.
  • FIGS. 2A-2B are three-dimensional surface graphs showing that the combination of Compound 1 and Compstatin synergistically inhibit complement-mediated hemolysis of PNH erythrocytes.
  • Each of the surface graphs have distinct and consistent positive peaks and as described in Example 2, substantial synergy volume.
  • the concentration of Compstatin ( ⁇ M) is measured on the x-axis and the concentration of Compound 1 ( ⁇ M) is measured on the y-axis.
  • the z-axis represents the difference between measured inhibition and a theoretically determined additive inhibition.
  • the positive surface peaks indicate greater inhibition than expected and therefore synergy, while negative surface peaks indicate less inhibition than expected and therefore antagonism.
  • FIGS. 3A-3D are three-dimensional surface graphs showing that the combination of Compound 1 and Compstatin synergistically inhibit CAP activity as measured using hemolysis of rabbit erythrocytes.
  • Each of the surface graphs have distinct and consistent positive peaks and as described in Example 6, substantial synergy volume.
  • the concentration of Compstatin ( ⁇ M) is measured on the x-axis and the concentration of Compound 1 ( ⁇ M) is measured on the y-axis.
  • the z-axis represents the difference between measured inhibition and a theoretically determined additive inhibition.
  • the positive surface peaks indicate greater inhibition than expected and therefore synergy, while negative surface peaks indicate less inhibition than expected and therefore antagonism.
  • FIGS. 4A-4C are the three-dimensional surface graphs showing that the combination of Compound 1 and anti-C5 (murine monoclonal antibody to human C5, isotype IgG1K, product No. A217 from Quidel, San Diego, Calif.) are moderate synergistic inhibitors of CAP activity as measured using the Wieslab ELISA-based functional assay.
  • Each of the surface graphs have distinct positive peaks and as described in Example 7, synergy volume.
  • the concentration of anti-C5 ( ⁇ g/mL) is measured on the x-axis and the concentration of Compound 1 ( ⁇ M) is measured on the y-axis.
  • the z-axis represents the difference between measured inhibition and a theoretically determined additive inhibition.
  • the positive surface peaks indicate greater inhibition than expected and therefore synergy.
  • FIGS. 5A-5C are the three-dimensional surface graphs showing that the combination of Compound 1 and FUT-175 are moderate synergistic inhibitors of CAP activity as measured using hemolysis of rabbit erythrocytes.
  • Each of the surface graphs have distinct positive peaks and as described in Example 8, synergy volume.
  • the concentration of FUT-175 ( ⁇ M) is measured on the x-axis and the concentration of Compound 1 ( ⁇ M) is measured on the y-axis.
  • the z-axis represents the difference between measured inhibition and a theoretically determined additive inhibition.
  • the positive surface peaks indicate greater inhibition than expected and therefore synergy, while negative surface peaks indicate less inhibition than expected and therefore antagonism.
  • FIGS. 6A-6L are flow cytometry analyses of C3 fragment deposition on rabbit erythrocytes in the presence of serum and increasing concentrations of Compound 1.
  • Cell surface C3 fragments were detected with anti-human C3c antibody as described in Example 11.
  • the x-axis is the number of cells that stained positive with anti-C3c antibody and the y-axis is intensity measured in counts.
  • FIG. 6M is a dose-response curve showing the percentage of C3 fragment positive cells in the presence of increasing concentrations of Compound 1 and Compstatin as discussed in Example 11.
  • the x-axis is the concentration of compound measured in ⁇ M and the y-axis is C3 fragment positive cells measured as a percent.
  • FIGS. 7A-7L are flow cytometry analyses of C3 fragment deposition on artificial PNH cells under the treatment of various concentrations of Compound 1 as described in Example 12.
  • the dot plots show the distribution of erythrocytes after being labeled with anti-human CD59 (y-axis) and anti-human C3c (x-axis) antibodies.
  • FIG. 7M is a dose-response curve showing the percentage of C3 fragment positive cells in the presence of increasing concentrations of Compound 1 and Compstatin as discussed in Example 12.
  • the x-axis is the concentration of compound measured in ⁇ M and the y-axis is C3 fragment positive cells measured as a percent.
  • FIG. 8 is a representative key for flow cytometry analyses of C3 fragment deposition on intact and fragmented PNH erythrocytes.
  • the upper left quadrant is negative for C3 fragment deposition on intact PNH erythrocytes.
  • the lower left quadrant is negative for C3 fragment deposition on fragmented PNH erythrocytes.
  • the upper right quadrant is positive for C3 fragment deposition on intact PNH erythrocytes.
  • the lower right quadrant is positive for C3 fragment deposition on fragmented PNH erythrocytes.
  • the x-axis is increasing amounts of C3 convertase and the y-axis is the scatter intensity.
  • FIG. 9 is an evaluation of C3 fragment deposition on PNH erythrocytes under various conditions including no serum, osmotic lysis, heat inactivated serum, and serum.
  • the dot plots show the distribution of erythrocytes after being labeled with anti-CD47 (positive) and anti-human CD59 (negative) and anti-human C3c (C3 fragment deposition) antibodies.
  • the x-axis is increasing amounts of C3 convertase and the y-axis is the scatter intensity.
  • FIG. 10 is an evaluation of C3 fragment deposition on PNH erythrocytes with increasing concentrations of Compound 1 alone.
  • the dot plots show the distribution of erythrocytes after being labeled with anti-CD47 (positive) and anti-human CD59 (negative) and anti-human C3c (C 3 fragment deposition) antibodies.
  • the x-axis is increasing amounts of C3 convertase and the y-axis is the scatter intensity.
  • FIG. 11 is an evaluation of C3 fragment deposition on PNH erythrocytes with eculizumab alone, Compound 1 alone, and the combination of eculizumab and Compound 1.
  • the dot plots show the distribution of erythrocytes after being labeled with anti-CD47 (positive) and anti-human CD59 (negative) and anti-human C3c (C3 fragment deposition) antibodies.
  • the x-axis is increasing amounts of C3 convertase and the y-axis is the scatter intensity.
  • FIG. 12 is a bar-graph showing the inhibition of PNH erythrocyte hemolysis under physiological conditions with increasing levels of Compound 1, eculizumab alone, and the combination of eculizumab and Compound 1.
  • the x-axis is the compound dose and the y-axis is the percent inhibition of hemolysis.
  • FIG. 13A is a line graph showing observed lactate dehydrogenase levels found in blood collected from two PNH subjects treated with 100 mg. of Compound 1 in combination with intravenous eculizumab over multiple time points.
  • the x-axis includes the specific timepoints Day 1 (baseline), Week 1, Week 2, and Week 4.
  • the y-axis is the concentration of lactate dehydrogenase in blood measured in U/L.
  • FIG. 13B is a line graph showing the change from baseline of lactate dehydrogenase levels found in blood collected from two PNH subjects treated with 100 mg. of Compound 1 in combination with intravenous eculizumab over multiple time points.
  • the x-axis includes the specific timepoints Day 1 (baseline), Week 1, Week 2, and Week 4.
  • the y-axis is the change in concentration of lactate dehydrogenase from baseline in blood measured in U/L.
  • FIG. 14A is a line graph showing observed hemoglobin levels found in blood collected from two PNH subjects treated with 100 mg. of Compound 1 in combination with intravenous eculizumab over multiple time points.
  • the x-axis includes the specific timepoints Day 1 (baseline), Week 1, Week 2, and Week 4.
  • the y-axis is the concentration of hemoglobin in blood measured in g/dL.
  • FIG. 14B is a line graph showing the change from baseline of hemoglobin levels found in blood collected from two PNH subjects treated with 100 mg of Compound 1 in combination with intravenous eculizumab over multiple time points.
  • the x-axis includes the specific timepoints Day 1 (baseline), Week 1, Week 2, and Week 4.
  • the y-axis is the change in concentration of hemoglobin from baseline in blood measured in g/dL.
  • FIG. 15A is a line graph showing the observed reticulocyte levels found in blood collected from two PNH subjects treated with 100 mg of Compound 1 in combination with intravenous eculizumab over multiple time points.
  • the x-axis includes the specific timepoints Day 1 (baseline), Week 1, Week 2, and Week 4.
  • the y-axis is the concentration of reticulocytes in blood measured in 10 9 /L.
  • FIG. 15B is a line graph showing the change from baseline of reticulocyte levels found in blood collected from two PNH subjects treated with 100 mg of Compound 1 in combination with intravenous eculizumab over multiple time points.
  • the x-axis includes the specific timepoints Day 1 (baseline), Week 1, Week 2, and Week 4.
  • the y-axis is the change in number of reticulocytes from baseline in blood measured in 10 9 /L.
  • FIG. 16A is a line graph showing the observed PNH erythrocyte Type III percentage found in blood collected from two PNH subjects treated with 100 mg of Compound 1 in combination with intravenous eculizumab over multiple time points.
  • the x-axis includes the specific timepoints Day 1 (baseline), Week 2, and Week 4.
  • the y-axis is the percentage of PNH erythrocyte Type III in blood.
  • FIG. 16B is a line graph showing the change from baseline of percentage PNH erythrocytes Type III found in blood collected from two PNH subjects treated with 100 mg of Compound 1 in combination with intravenous eculizumab over multiple time points.
  • the x-axis includes the specific timepoints Day 1 (baseline), Week 2, and Week 4.
  • the y-axis is the change in percentage of PNH erythrocytes Type III from baseline in blood.
  • FIG. 17A is a line graph showing the observed C3 fragment deposition percentage found in blood collected from two PNH subjects treated with 100 mg of Compound 1 in combination with intravenous eculizumab over multiple time points.
  • the x-axis includes the specific timepoints Day 1 (baseline), Week 2, and Week 4.
  • the y-axis is the percentage of C3 fragment deposition in blood.
  • FIG. 17B is a line graph showing the change from baseline of the percentage of C3 fragment deposition found in blood collected from two PNH subjects treated with 100 mg of Compound 1 in combination with intravenous eculizumab over multiple time points.
  • the x-axis includes the specific timepoints Day 1 (baseline), Week 2, and Week 4.
  • the y-axis is the change in percentage of C3 fragment deposition from baseline in blood.
  • PNH Paroxysmal Nocturnal Hemoglobinuria
  • HSC clonal hematopoietic stem cell
  • a CFD inhibitor selected from Formula I or II in combination with C5 inhibitors, C3, inhibitors, CFB inhibitors, or a pan-complement inhibitor, or a combination thereof.
  • the “subject” treated is typically a human subject, although it is to be understood the methods described herein are effective with respect to other animals, such as mammals and vertebrate species. More particularly, the term “subject” can include animals used in assays such as those used in preclinical testing including but not limited to mice, rats, monkeys, dogs, pigs and rabbits; as well as domesticated swine (pigs and hogs), ruminants, equine, poultry, felines, bovines, murines, canines, and the like.
  • pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with subjects (e.g., human subjects) without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the presently disclosed subject matter.
  • salt refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the presently disclosed subject matter. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified Compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed.
  • Pharmaceutically acceptable base addition salts may be formed with metals or amines, such as alkali and alkaline earth metal hydroxides, or of organic amines. Examples of metals used as cations, include, but are not limited to, sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines include, but are not limited to, N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine.
  • Salts can be prepared from inorganic acids sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, phosphorus, and the like.
  • Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate, laurylsulphonate and isethionate salts, and the like.
  • Salts can also be prepared from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. and the like.
  • organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. and the like.
  • Representative salts include acetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like.
  • Pharmaceutically acceptable salts can include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Also contemplated are the salts of amino acids such as arginate, gluconate, galacturonate, and the like. See, for example, Berge et al., J. Pharm. Sci., 1977, 66, 1-19, which is incorporated herein by reference.
  • compositions are compositions comprising at least one active agent, and at least one other substance, such as a pharmaceutically acceptable carrier or pharmaceutically acceptable excipient.
  • a “pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise inappropriate for administration to a host, typically a human. In one embodiment, an excipient is used that is acceptable for veterinary use.
  • the term “prodrug” means a compound which when administered to a host in vivo is converted into the parent drug.
  • parent drug means any of the presently described chemical compounds that are useful to treat any of the disorders described herein, or to control or improve the underlying cause or symptoms associated with any physiological or pathological disorder described herein in a host, typically a human.
  • Prodrugs can be used to achieve any desired effect, including to enhance properties of the parent drug or to improve the pharmaceutic or pharmacokinetic properties of the parent.
  • Prodrug strategies exist which provide choices in modulating the conditions for in vivo generation of the parent drug, all of which are deemed included herein.
  • Nonlimiting examples of prodrug strategies include covalent attachment of removable groups, or removable portions of groups, for example, but not limited to acylation, phosphorylation, phosphonylation, phosphoramidate derivatives, amidation, reduction, oxidation, esterification, alkylation, other carboxy derivatives, sulfoxy or sulfone derivatives, carbonylation or anhydride, among others.
  • the compounds of Formula I or Formula II include desired isotopic substitutions of atoms, at amounts above the natural abundance of the isotope, i.e., enriched.
  • Isotopes are atoms having the same atomic number but different mass numbers, i.e., the same number of protons but a different number of neutrons.
  • isotopes of hydrogen for example, deuterium ( 2 H) and tritium ( 3 H) may be used anywhere in described structures.
  • isotopes of carbon e.g., 13 C and u may be used.
  • a preferred isotopic substitution is deuterium for hydrogen at one or more locations on the molecule to improve the performance of the drug.
  • the deuterium can be bound in a location of bond breakage during metabolism (an ⁇ -deuterium kinetic isotope effect) or next to or near the site of bond breakage (a (3-deuterium kinetic isotope effect).
  • substitution with isotopes such as deuterium can afford certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements.
  • Substitution of deuterium for hydrogen at a site of metabolic break down can reduce the rate of, or eliminate, the metabolism at that bond.
  • the hydrogen atom can be any isotope of hydrogen, including protium ( 1 H), deuterium ( 2 H) and tritium ( 3 H).
  • isotopically-labeled refers to an analog that is a “deuterated analog”, a “ 13 C-labeled analog,” or a “deuterated/ 13 C-labeled analog.”
  • deuterated analog means a compound described herein, whereby a H-isotope, i.e., hydrogen/protium ( 1 H), is substituted by a H-isotope, i.e., deuterium ( 2 H).
  • Deuterium substitution can be partial or complete. Partial deuterium substitution means that at least one hydrogen is substituted by at least one deuterium.
  • the isotope is 90%, 95%, or 99% or more enriched in an isotope at any location of interest. In some embodiments, it is deuterium that is 90%, 95%, or 99% enriched at a desired location.
  • PNH is caused by somatic mutations in PIGA in bone marrow stem cells. Because stem cells give rise to all mature blood elements, including red blood cells, white blood cells, and platelets, cells derived from an abnormal stem cell will also carry the PIGA mutation. Cells harboring the PIGA mutation are deficient in a class of proteins called GPI-anchored proteins that are important for anchoring proteins in the cell membrane. Two important proteins that are unable to attach to the cell membrane via a GPI-anchor in PIGA-mutated cells are the CD59 glycoprotein (CD59) and the decay-accelerating factor (DAF, also known as CD55). These proteins are important for regulating the complement system, and their absence on the cell surface results in their susceptibility to destruction. The destruction of red blood cells (hemolysis), extravascular and intravascular, is associated with PNH.
  • CD59 CD59 glycoprotein
  • DAF decay-accelerating factor
  • red blood cells lyse in circulation and release hemoglobin into the plasma (hemoglobinemia).
  • One way to measure intravascular hemolysis is a test that measures the level of the enzyme lactate dehydrogenase (LDH). Subjects with PNH experiencing intravascular hemolysis have elevated levels of LDH.
  • LDH lactate dehydrogenase
  • red blood cells are phagocytized by macrophages. Extravascular hemolysis can be tracked indirectly by the continued loss of red blood cells (monitored by hemoglobin and transfusion dependence, i.e., the number of transfusions required over a specified time period).
  • the reticulocyte counts In subjects with PNH, the reticulocyte counts often remain elevated during treatment with eculizumab, because of the persistence of some extravascular hemolysis due to deposition of C3 fragments on PNH red cells. Additionally, extravascular hemolysis will result in increased presentation of unconjugated bilirubin to the hepatocyte. If the ability of the hepatocyte to take up and conjugate this bilirubin is overwhelmed, unconjugated bilirubin will accumulate in plasma, causing an increase in total and indirect bilirubin.
  • eculizumab a monoclonal antibody inhibitor that binds to C5 and prevents the generation of C5a and C5b. While this prevents complement-mediated intravascular hemolysis, eculizumab leads to increased deposition of complement C 3 fragments on PNH cells that may result in extravascular hemolysis. Eculizumab is unable to treat extravascular hemolysis, and therefore, even if intravascular hemolysis is prevented with eculizumab treatment, subjects can still experience extravascular hemolysis. A number of subjects (“partial responders” or “suboptimal responders”) continue to suffer from anemia due to either incomplete inhibition of intravascular hemolysis or extravascular hemolysis.
  • Factor D inhibitors for use in the present invention are selected from Formula I or Formula II:
  • R 1 is hydrogen
  • R 1 is C 1 -C 3 alkyl.
  • R 1 is methyl
  • R 1 is ethyl
  • R 1 is halogen
  • Non-limiting examples of compounds of Formula I and II are provided below in Table 1.
  • An exemplary CFD inhibitor for use in the present invention is, for example, Compound 1.
  • Factor D inhibitor ((2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide) (Compound 1) has been previously described, see U.S. Patent Appl. Pub. 2015/0239895 and 2017/0066783. Compound 1 may be synthesized by methods known to those in the art.
  • tert-butyl 2-(3-acetyl-5-bromo-1H-indazol-1-yl)acetate (S1) is coupled to 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine using tetrakis(triphenylphosphine)palladium(0) in the presence of base to provide tert-butyl 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (S2).
  • step 2 hydrolysis of tert-butyl 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (S2) with trifluoroacetic acid provides 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (S3).
  • step 3 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (S3) and (2S,4R)—N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (S4) are coupled using HATU to provide (2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimi din-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (1).
  • kits for treating PNH in a subject comprising administering to the subject an effective amount of a C5 inhibitor in combination or alternation with an effective amount of a CFD inhibitor selected from Formula I or Formula II.
  • the C5 inhibitor is a monoclonal antibody targeting C5.
  • the C5 inhibitor is eculizumab (SolirisTM Alexion Pharmaceuticals, New Haven, Conn., see, e.g., U.S. Pat. No. 9,352,035).
  • the C5 inhibitor may be, but is not limited to: a recombinant human minibody, for example Mubodina® (monoclonal antibody, Adienne Pharma and Biotech, Bergamo, Italy; see U.S. Pat. No. 7,999,081); coversin (small animal protein, Volution Immuno-pharmaceuticals, Geneva, Switzerland; see e.g. Penabad et al. Lupus, 2012, 23(12):1324-6); LFG316 (monoclonal antibody, Novartis, Basel, Switzerland, and Morphosys, Planegg, Germany; see U.S. Pat. Nos.
  • Mubodina® monoclonal antibody, Adienne Pharma and Biotech, Bergamo, Italy
  • coversin small animal protein, Volution Immuno-pharmaceuticals, Geneva, Switzerland; see e.g. Penabad et al. Lupus, 2012, 23(12):1324-6
  • LFG316 monoclonal antibody, Novartis, Basel, Switzerland, and Morpho
  • ARC-1905 pegylated RNA aptamer, Ophthotech, Princeton, N.J. and New York, N.Y.; see Keefe et al., Nature Reviews Drug Discovery, 9, 537-550
  • RA101348 and RA101495 microcyclic peptides, Ra Pharmaceuticals, Cambridge, Mass.
  • SOBI002 affibody, Swedish Orphan Biovitrum, Sweden
  • ALN-CCS Si-RNA, Alnylam Pharmaceuticals, Cambridge, Mass.
  • ARC1005 aptamers, Novo Nordisk, Bagsvaerd, Denmark
  • SOMAmers aptamers, SomaLogic, Boulder, Co
  • SSL7 bacterial protein toxin, see, e.g.
  • RG6107 anti-C5 recycling antibody, Roche Pharmaceuticals, Basel, Switzerland
  • ALXN1210 and ALXN5500 monoclonal antibodies, Alexion Pharmaceuticals, New Haven, Conn.
  • TT30 fusion protein, Alexion Pharmaceuticals, New Haven, Conn.
  • REGN3918 monoclonal antibody, Regeneron, Tarrytown, N.Y.
  • ABP959 eculizumab biosimilar, Amgen, Thousand Oaks, Calif.
  • the C5 inhibitor is a recombinant human minibody, for example Mubodina®.
  • Mubodina® is a fully human recombinant antibody C5 developed by Adienne Pharma and Biotech. Mubodina® is described in U.S. Pat. No. 7,999,081.
  • the C5 inhibitor is coversin.
  • Coversin is a recombinant protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick currently developed as a recombinant protein by Akari Therapeutics. Coversin is described in Penabad et al. Lupus 2012, 23(12):1324-6.
  • the C5 inhibitor is Tesidolumab/LFG316.
  • Tesidolumab is a monoclonal antibody developed by Novartis and Morphosys. Tesidolumab is described in U.S. Pat. Nos. 8,241,628 and 8,883,158.
  • the C5 inhibitor is ARC-1905.
  • ARC-1905 is a pegylated RNA aptamer developed by Ophthotech. ARC-1905 is described in Keefe et al. Nature Reviews Drug Discovery, 9:537-550.
  • the C5 inhibitor is RA101348.
  • RA101348 is a macrocyclic peptide developed by Ra Pharmaceuticals.
  • the C5 inhibitor is RA101495.
  • RA101495 is a macrocyclic peptide developed by Ra Pharmaceuticals.
  • the C5 inhibitor is SOBI002.
  • SOBI002 is an affibody developed by the Swedish Orphan Biovitrum.
  • the C5 inhibitor is ARC1005.
  • ARC1005 is an aptamer developed by Novo Nordisk.
  • the C5 inhibitor is SOMAmers for C5.
  • SOMAmers are aptamers developed by SomaLogic.
  • the C5 inhibitor is SSL7.
  • SSL7 is a bacterial protein toxin described in Laursen et al. Proc. Natl. Acad. Sci. U.S.A., 107(8):3681-6.
  • the C5 inhibitor is MEDI7814.
  • MEDI7814 is a monoclonal antibody developed by Medlmmune.
  • the C5 inhibitor is aurin tricarboxylic acid. In another embodiment, the C5 inhibitor is an aurin tricarboxylic acid derivative. These aurin derivatives were developed by Aurin Biotech and are further described in U.S. Patent Appl. Pub. No. 2013/003592).
  • the C5 inhibitor is RG6107/SKY59.
  • RG6107/SKY59 is an anti-05 recycling antibody developed by Roche Pharmaceuticals.
  • the C5 inhibitor is ALXN1210. In another embodiment, the C5 inhibitor is ALXN5500. ALXN1210 and ALXN5500 are monoclonal antibodies developed by Alexion Pharmaceuticals.
  • the C5 inhibitor is TT30.
  • TT30 is a fusion protein developed by Alexion Pharmaceuticals.
  • the C5 inhibitor is ABP959.
  • ABP959 is an eculizamab biosimilar monoclonal antibody developed by Amgen.
  • the C5 inhibitor is Anti-05 siRNA.
  • Anti-05 siRNA was developed by
  • the C5 inhibitor is Erdigna.
  • Erdigna® is an antibody developed by Adienne Pharma.
  • the C5 inhibitor is avacincaptad pegol/Zimura®.
  • Avacincaptad pegol is in aptamer developed by Opthotech.
  • the C5 inhibitor is SOBI005.
  • SOBI005 is a protein in developed by the Swedish Orphan Biovitrum.
  • the C5 inhibitor is ISU305.
  • ISU305 is a monoclonal antibody developed by ISU ABXIS.
  • the C5 inhibitor is REGN3918.
  • REGN3918 is a monoclonal antibody developed by Regeneron.
  • kits for treating PNH in a subject comprising administering to the subject an effective amount of a C3 inhibitor in combination or alternation with an effective amount of a CFD inhibitor selected from Formula I or Formula II.
  • C3 inhibitors are known in the art.
  • Compound 1 is administered in combination or alternation with compstatin and/or a compstatin analog.
  • Compstatin and compastin analogs are known and are found to be useful inhibitors of C3, see U.S. Pat. Nos. 9,056,076; 8,168,584; 9,421,240; 9,291,622; 8,580,735; 9,371,365; 9,169,307; 8,946,145; 7,989,589; 7,888,323; 6,319,897; and US Patent Appl. Pub. Nos.
  • the compstatin analog having the amino acid sequence ICVVQDWGHHCRT (SEQ. ID. NO. 1).
  • the C3 inhibitor is a compstatin analog.
  • the compstatin analog is 4(1MeW)/APL-1 of the sequence Ac-ICV(1-mW)QDWGAHRCT (SEQ. ID. NO. 2), wherein Ac is acetyl and 1-mW is 1-methyltryptophan.
  • the compstatin analog is Cp40/AMY-101, which has an amino acid sequence yICV(1 mW)QDW-Sar-AHRC-mI (SEQ. ID. NO. 3), wherein y is D-tyrosine, 1 mW is 1-methyltryptophan, Sar is sarcosine, and mI is N-methylisoleucine.
  • the compstatin analog is PEG-Cp40, having the amino acid sequence PEG-yICV(1 mW)QDW-Sar-AHRC-mI (SEQ. ID. NO.
  • the compstatin analog is 4(1MeW)POT-4. 4(1MeW)POT-4 was developed by Potentia. In yet another embodiment, the compstatin analog is AMY-201. AMY-201 was developed by Amyndas Pharmaceuticals.
  • Compound 1 can be combined with C3 inhibitors that include, but are not limited to: H17 (monoclonal antibody, EluSys Therapeutics, Pine Brook, N.J.); mirococept (CR1-based protein); sCR1 (CR1-based protein, Celldex, Hampton, N.J.); TT32 (CR-1 based protein, Alexion Pharmaceuticals, New Haven, Conn.); HC-1496 (recombinant peptide); CB 2782 (enzyme, Catalyst Biosciences, South San Francisco, Calif.); APL-2 (pegylated synthetic cyclic peptide, Apellis Pharmaceuticals, Crestwood, Ky.); or combinations thereof.
  • C3 inhibitors include, but are not limited to: H17 (monoclonal antibody, EluSys Therapeutics, Pine Brook, N.J.); mirococept (CR1-based protein); sCR1 (CR1-based protein, Celldex, Hampton, N.J.); TT32 (CR-1 based
  • the C3 inhibitor is H17.
  • H17 is a humanized monoclonal antibody in development by EluSys Therapeutics. H17 is described in Paixao-Cavalcante et al. J. Immunol. 2014, 192(10):4844-4851.
  • the C3 inhibitor is mirococept.
  • Mirococept is a CR1-based protein developed by Inflazyme Pharmaceuticals.
  • the C3 inhibitor is sCR1.
  • sCR1 is a soluble form of the CR1 protein developed by Celldex.
  • the C3 inhibitor is TT32.
  • TT32 is a CR-1 based protein developed by Alexion Pharmaceuticals.
  • the C3 inhibitor is HC-1496.
  • HC-1496 is a recombinant peptide developed by InCode.
  • the C3 inhibitor is CB 2782.
  • CB 2782 is novel protease derived from human membrane type serine protease 1 (MTSP-1) that was developed by Catalyst Biosciences.
  • the C3 inhibitor is APL-2.
  • APL-2 is a pegylated version of APL-1 developed by Apellis Pharmaceuticals.
  • CFB inhibitors are known in the art.
  • Compound 1 can be combined with CFB inhibitors that include, but are not limited to: anti-FB SiRNA (Alnylam Pharmaceuticals, Cambridge, Mass.); TA106 (monoclonal antibody, Alexion Pharmaceuticals, New Haven, Conn.); LNP023 (small molecule, Novartis, Basel, Switzerland); SOMAmers (aptamers, SomaLogic, Boulder, Colo.); bikaciomab (Novelmed Therapeutics, Cleveland, Ohio); complin (see, Kadam et al., J. Immunol.
  • CFB inhibitors that can be combined with Compound 1 as described herein include those disclosed in PCT/US17/39587.
  • CFB inhibitors that can be combined with Compound 1 as described herein include those disclosed in PCT/US17/014458.
  • CFB inhibitors that can be combined with Compound 1 as described herein include those disclosed in U.S. Patent Appl. Pub. No. 2016/0024079 (assigned to Novartis AG).
  • the CFB inhibitor is
  • the CFB inhibitor is anti-FB siRNA.
  • Anti-FB siRNA was developed by Alnylam Pharmaceuticals.
  • the CFB inhibitor is TA106.
  • TA106 is a monoclonal antibody developed by Alexion Pharmaceuticals.
  • the CFB inhibitor is LNP023.
  • LNP023 is a small molecule inhibitor of CFB developed by Novartis. LNP023 and related inhibitors are described in Maibaum et al. Nat. Chem. Biol. 2016, 12:1105-1110.
  • the CFB inhibitor is complin.
  • Complin is a peptide inhibitor that is described in Kadam et al. J. Immunol. 2010 184(12):7116-24.
  • the CFB inhibitor is Ionis-FB-L Rx .
  • Ionis-FB-L Rx is a ligand conjugated antisense drug developed by Ionis Pharmaceuticals.
  • pan-inhibitor of complement components in combination or alternation with Compound 1.
  • Pan-inhibitors of complement components are known in the art.
  • the inhibitor is FUT-175.
  • the present invention provides methods of treating a subject with PNH comprising administering to the subject a C5, C3, and/or pan-complement inhibitor in combination or alternation with a CFD inhibitor selected from Formula I or Formula II described herein, or a pharmaceutically acceptable salt thereof, including, but not limited to Compound 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
  • a method of treating a subject with PNH comprising administrating to the subject a therapeutically effective amount of a C5 inhibitor in combination with a therapeutically effective amount of a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof in a particular embodiment, the C5 inhibitor is a monoclonal antibody to C5.
  • the C5 inhibitor is eculizamab.
  • the C5 inhibitor is a recombinant human minibody, for example Mubodina®
  • the C5 inhibitor is coversin ( Akari Therapeutics). In one embodiment, the C5 inhibitor is Tesidolumab/LFG316 (Novartis/Morphosys). In one embodiment, the C5 inhibitor is ARC-1905 (Ophthotech). In one embodiment, the C5 inhibitor is RA101348 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is RA101495 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is SOBI002 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ARC1005 (Novo Nordisk). In one embodiment, the C5 inhibitor is a SOMAmer for C5 (SomaLogic).
  • the C5 inhibitor is SSL7. In one embodiment, the C5 inhibitor is MEDI7814 (MedImmune). In one embodiment, the C5 inhibitor is aurin tricarboxylic acid (Aurin Biotech). In another embodiment, the C5 inhibitor is an aurin tricarboxylic acid derivative (Aurin Biotech). In one embodiment, the C5 inhibitor is RG6107/SKY59 (Roche Pharmaceuticals). In one embodiment, the C5 inhibitor is ALXN1210 (Alexion Pharmaceuticals). In another embodiment, the C5 inhibitor is ALXN5500 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is TT30 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is ABP959 (Amgen).
  • the C5 inhibitor is Anti-05 siRNA (Alnylam Pharmaceuticals). In one embodiment, the C5 inhibitor is Erdigna (Adienne Pharma). In one embodiment, the C5 inhibitor is avacincaptad pegol/Zimura® (Ophthotech). In one embodiment, the C5 inhibitor is SOBI005 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ISU305 (ISU ABXIS). In one embodiment, the C5 inhibitor is REGN3918 (Regeneron). In one embodiment, the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor. In one embodiment, the CFD inhibitor is Compound 1. In one embodiment, the CFD inhibitor is Compound 2.
  • the CFD inhibitor is Compound 3. In one embodiment, the CFD inhibitor is Compound 4, In one embodiment, the CFD inhibitor is Compound 5. In one embodiment, the CFD inhibitor is Compound 6. In one embodiment, the CFI) inhibitor is Compound 7. In one embodiment, the CFI) inhibitor is Compound 8. In one embodiment, the CFD inhibitor is Compound 9. In one embodiment, the CFD inhibitor is Compound 10, In one embodiment, the CFD inhibitor is Compound 11, In one embodiment, the CFD inhibitor is Compound 12. In one embodiment, the CFD inhibitor is Compound 13. In one embodiment, the CFD inhibitor is Compound 14. In one embodiment, the CFD inhibitor is Compound 15. In one embodiment, the CFD inhibitor is Compound 16. In one embodiment, the CFD inhibitor is Compound 17.
  • the CFD inhibitor is Compound 18. In one embodiment, the CM inhibitor is Compound 19. In one embodiment, the CFI) inhibitor is Compound 20. In one embodiment, the CFD inhibitor is Compound 21. In one embodiment, the CFI) inhibitor is Compound 22. In one embodiment, the CFI) inhibitor is Compound 23. In one embodiment, the CFD inhibitor is Compound 24. In one embodiment, the CFD inhibitor is Compound 25. In one embodiment, 100 mg of Compound 1 is administered three times a day. In one embodiment, 150 mg of Compound 1 is administered three times a day. in one embodiment, 200 mg of Compound 1 is administered three times a day.
  • a method of treating a subject with PNH comprising administering to the subject a therapeutically effective amount of a C5 inhibitor in alternation with a therapeutically effective amount of a CFD inhibitor selected from a compound of Formula I or
  • the C5 inhibitor is a monoclonal antibody to C5, In one embodiment, the C5 inhibitor is eculizarnab. In one embodiment, the C5 inhibitor is a recombinant human minibody, for example Mubodina® (Adienne Pharma and Biotech). In one embodiment, the C5 inhibitor is coversin ( Akari Therapeutics). In one embodiment, the C5 inhibitor is Tesidolumab/LFG316
  • the C5 inhibitor is ARC-1905 (Ophthotech). In one embodiment, the C5 inhibitor is RA101348 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is RA101495 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is SOBI002 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ARC1005 (Novo Nordisk). In one embodiment, the C5 inhibitor is a SOMAmer for C5 (SomaLogic). In one embodiment, the C5 inhibitor is SSL7. In one embodiment, the C5 inhibitor is MEDI7814 (MedImmune).
  • the C5 inhibitor is aurin tricarboxylic acid (Aurin Biotech). In another embodiment, the C5 inhibitor is an aurin tricarboxylic acid derivative (Aurin Biotech). In one embodiment, the C5 inhibitor is RG6107/SKY59 (Roche Pharmaceuticals). In one embodiment, the C5 inhibitor is ALXN1210 (Alexion Pharmaceuticals). In another embodiment, the C5 inhibitor is ALXN5500 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is TT30 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is ABP959 (Amgen). In one embodiment, the C5 inhibitor is Anti-C5 siRNA (Alnylam Pharmaceuticals).
  • the C5 inhibitor is Erdigna (Adienne Pharma). In one embodiment, the C5 inhibitor is avacincaptad pegol/Zimura® (Ophthotech). In one embodiment, the C5 inhibitor is SOBI005 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ISU305 (ISU ABXIS). In one embodiment, the C5 inhibitor is REGN3918 (Regeneron). In one embodiment, the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor. In one embodiment, the CFD inhibitor is Compound 1. In one embodiment, the CFD inhibitor is Compound 2. In one embodiment, the CFD inhibitor is Compound 3. In one embodiment, the CFD inhibitor is Compound 4.
  • the CFD inhibitor is Compound 5. in one embodiment, the CFI) inhibitor is Compound 6. in one embodiment, the CFD inhibitor is Compound 7. In one embodiment, the CFD inhibitor is Compound 8. In one embodiment, the CFD inhibitor is Compound 9. In one embodiment, the CFI) inhibitor is Compound 10. In one embodiment, the CFD inhibitor is Compound 11. In one embodiment, the CFD inhibitor is Compound 12. In one embodiment, the CFD inhibitor is Compound 13, In one embodiment, the CFD inhibitor is Compound 14. In one embodiment, the CFD inhibitor is Compound 15. In one embodiment, the CFD inhibitor is Compound 16. In one embodiment, the CFD inhibitor is Compound 17, In one embodiment, the CFD inhibitor is Compound 18. In one embodiment, the CFD inhibitor is Compound 19.
  • the CFD inhibitor is Compound 20. In one embodiment, the CM inhibitor is Compound 21. In one embodiment, the CFD inhibitor is Compound 22. In one embodiment, the CFD inhibitor is Compound 23. In one embodiment, the CFD inhibitor is Compound 24. In one embodiment, the CFD inhibitor is Compound 25. In one embodiment, 100 mg of Compound 1 is administered three times a day. In one embodiment, 150 mg of Compound 1 is administered three times a day. In one embodiment, 200 mg of Compound 1 is administered three times a day.
  • a method of treating a subject with PNH comprising administering to the subject a therapeutically effective amount of a C5 inhibitor in combination or alternation with a therapeutically effective amount of a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, wherein the subject has a genetic polymorphism of the Complement Receptor 1 gene (CR1).
  • the CR1 polymorphism is the HindIII H/L genotype.
  • the CR1 polymorphism is the HindIII L/L genotype.
  • the C5 inhibitor is a monoclonal antibody to C5.
  • the C5 inhibitor is eculizamab.
  • the C5 inhibitor is a recombinant human minibody, for example Mubodina® (Adienne Pharma and Biotech). In one embodiment, the C5 inhibitor is coversin (Akari Therapeutics). In one embodiment, the C5 inhibitor is Tesidolumab/LFG316 (Novartis/Morphosys). In one embodiment, the C5 inhibitor is ARC-1905 (Ophthotech). In one embodiment, the C5 inhibitor is RA101348 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is RA101495 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is SOBI002 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ARC1005 (Novo Nordisk).
  • the C5 inhibitor is a SOMAmer for C5 (SomaLogic). In one embodiment, the C5 inhibitor is SSL7. In one embodiment, the C5 inhibitor is MEDI7814 (MedImmune). In one embodiment, the C5 inhibitor is aurin tricarboxylic acid (Aurin Biotech). In another embodiment, the C5 inhibitor is an aurin tricarboxylic acid derivative (Aurin Biotech). In one embodiment, the C5 inhibitor is RG6107/SKY59 (Roche Pharmaceuticals). In one embodiment, the C5 inhibitor is ALXN1210 (Alexion Pharmaceuticals). In another embodiment, the C5 inhibitor is ALXN5500 (Alexion Pharmaceuticals).
  • the C5 inhibitor is TT30 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is ABP959 (Amgen). In one embodiment, the C5 inhibitor is Anti-05 siRNA (Alnylam Pharmaceuticals). In one embodiment, the C5 inhibitor is Erdigna (Adienne Pharma). In one embodiment, the C5 inhibitor is avacincaptad pegol/Zimura® (Ophthotech). In one embodiment, the C5 inhibitor is SOBI005 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ISU305 (ISU ABXIS). In one embodiment, the C5 inhibitor is REGN3918 (Regeneron).
  • the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor.
  • the CM inhibitor is Compound 1.
  • the CFD inhibitor is Compound 2.
  • the CFD inhibitor is Compound 3.
  • the CFD inhibitor is Compound 4.
  • the CFD inhibitor is Compound 5.
  • the CFD inhibitor is Compound 6.
  • the CFD inhibitor is Compound 7 one embodiment, the CFD inhibitor is Compound 8.
  • the CFD inhibitor is Compound 9.
  • the CFD inhibitor is Compound 10.
  • the CFD inhibitor is Compound 11. In one embodiment, the CFD inhibitor is Compound 12.
  • the CFD inhibitor is Compound 13, In one embodiment, the CFD inhibitor is Compound 14, In one embodiment, the CFD inhibitor is Compound 15. In one embodiment, the CFD inhibitor is Compound 16. In one embodiment, the CFD inhibitor is Compound 17. In one embodiment, the CFD inhibitor is Compound 18. In one embodiment, the CFD inhibitor is Compound 19. In one embodiment, the CFD inhibitor is Compound 20. In one embodiment, the CFD inhibitor is Compound 21. In one embodiment, the CM inhibitor is Compound 22. In one embodiment, the CFD inhibitor is Compound 23. In one embodiment, the CFD inhibitor is Compound 24. In one embodiment, the CFD inhibitor is Compound 25, In one embodiment, 100 mg of Compound 1 is administered three times a day. In one embodiment, 150 mg of Compound 1 is administered three times a day. In one embodiment. 200 mg of Compound 1 is administered three times a. day.
  • a method of treating a subject with PNH comprising administering to the subject a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, wherein the subject at the time of administration of the CFD inhibitor has been or is currently on a therapeutic regimen comprising the administration of a C5 inhibitor and is experiencing residual intravascular hemolysis.
  • the subject has a hemoglobin level of less than about 12 g/dL. In one embodiment, the subject has a hemoglobin level of less than about 10 g/dL. In one embodiment, the subject has a hemoglobin level of less than about 8 g/dL. In one embodiment, the subject has an LDH level greater than the upper limit of normal.
  • the subject has an LDH level greater than about 250 U/L. In one embodiment, the subject has an LDH level greater than about 500 U/L.
  • the subject is blood transfusion dependent. In one embodiment, at the time of administration of the CFD inhibitor, the subject has received one or more blood transfusions within the prior twelve months. In one embodiment, the subject has had two or more blood transfusions within the prior six months. In one embodiment, the subject has had four or more blood transfusions within the prior six months.
  • the C5 inhibitor upon administration of the CFD inhibitor, the C5 inhibitor is no longer administered. In another particular embodiment, upon administration of the CFD inhibitor, the C5 inhibitor also continues to be administered.
  • the C5 inhibitor is a monoclonal antibody to C5.
  • the C5 inhibitor is eculizamab.
  • the C5 inhibitor is a recombinant human minibody, for example Mubodina® (Adienne Pharma and Biotech).
  • the C5 inhibitor is coversin ( Akari Therapeutics).
  • the C5 inhibitor is Tesidolumab/LFG316 (Novartis/Morphosys).
  • the C5 inhibitor is ARC-1905 (Ophthotech).
  • the C5 inhibitor is RA101348 (Ra Pharmaceuticals).
  • the C5 inhibitor is RA101495 (Ra Pharmaceuticals).
  • the C5 inhibitor is SOBI002 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ARC1005 (Novo Nordisk). In one embodiment, the C5 inhibitor is a SOMAmer for C5 (SomaLogic). In one embodiment, the C5 inhibitor is SSL7. In one embodiment, the C5 inhibitor is MEDI7814 (MedImmune). In one embodiment, the C5 inhibitor is aurin tricarboxylic acid (Aurin Biotech). In another embodiment, the C5 inhibitor is an aurin tricarboxylic acid derivative (Aurin Biotech). In one embodiment, the C5 inhibitor is RG6107/SKY59 (Roche Pharmaceuticals).
  • the C5 inhibitor is ALXN1210 (Alexion Pharmaceuticals). In another embodiment, the C5 inhibitor is ALXN5500 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is TT30 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is ABP959 (Amgen). In one embodiment, the C5 inhibitor is Anti-05 siRNA (Alnylam Pharmaceuticals). In one embodiment, the C5 inhibitor is Erdigna (Adienne Pharma). In one embodiment, the C5 inhibitor is avacincaptad pegol/Zimura® (Ophthotech). In one embodiment, the C5 inhibitor is SOBI005 (Swedish Orphan Biovitrum).
  • the C5 inhibitor is ISU305 (ISU ABXIS). In one embodiment, the C5 inhibitor is REGN3918 (Regeneron). In one embodiment, the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor.
  • the CFD inhibitor is Compound 1. In one embodiment, the CFD inhibitor is Compound 2. In one embodiment, the CFD inhibitor is Compound 3. In one embodiment, the CFD inhibitor is Compound 4, In one embodiment, the CFD inhibitor is Compound 5. In one embodiment, the CFD inhibitor is Compound 6. In one embodiment, the CFD inhibitor is Compound 7. In one embodiment, the CFD inhibitor is Compound 8. In one embodiment, the CFD inhibitor is Compound 9. In one embodiment, the CFD inhibitor is Compound 10.
  • the CFD inhibitor is Compound 11. In one embodiment, the CFD inhibitor is Compound 12. In one embodiment, the CFD inhibitor is Compound 13. In one embodiment, the CFD inhibitor is Compound 14. In one embodiment, the CFD inhibitor is Compound 15. In one embodiment, the CFD inhibitor is Compound 16, In one embodiment, the CFD inhibitor is Compound 17. In one embodiment, the CFD inhibitor is Compound 18. In one embodiment, the CFD inhibitor is Compound 19. In one embodiment, the CFD inhibitor is Compound 20. In one embodiment, the CFD inhibitor is Compound 21. In one embodiment, the CFD inhibitor is Compound 22. In one embodiment, the CFD inhibitor is Compound 23. In one embodiment, the CFD inhibitor is Compound 24. In one embodiment, the CFD inhibitor is Compound 25. In one embodiment, 100 mg of Compound 1 is administered three times a day. In one embodiment, 150 mg of Compound 1 is administered three times a day. In one embodiment, 200 mg of Compound 1 is administered three times a day.
  • a method of treating a subject with PNH comprising administering to the subject a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, wherein the subject at the time of administration of the CFD inhibitor has been on a therapeutic regimen comprising the administration of a C5 inhibitor and is experiencing extravascular hemolysis.
  • the subject has a hemoglobin level of less than about 12 g/dL. In one embodiment, the subject has a hemoglobin level of less than about 10 g/dL. In one embodiment, the subject has a hemoglobin level of less than about 8 g/dL. In one embodiment, the subject has an LDH level less than the upper limit of normal.
  • the subject has an LDH level less than about 250 U/L.
  • the subject is blood transfusion dependent.
  • the subject has received one or more blood transfusions within the prior twelve months.
  • the subject has had two or more blood transfusions within the prior six months.
  • the subject has had four or more blood transfusions within the prior six months.
  • the C5 inhibitor upon administration of the CFD inhibitor, is no longer administered.
  • the C5 inhibitor upon administration of the CFD inhibitor, the C5 inhibitor also continues to be administered.
  • the C5 inhibitor is a monoclonal antibody to C5.
  • the C5 inhibitor is eculizamab. In one embodiment, the C5 inhibitor is a recombinant human minibody, for example Mubodina® (Adienne Pharma and Biotech). In one embodiment, the C5 inhibitor is coversin (Akari Therapeutics). In one embodiment, the C5 inhibitor is Tesidolumab/LFG316 (Novartis/Morphosys). In one embodiment, the C5 inhibitor is ARC-1905 (Ophthotech). In one embodiment, the C5 inhibitor is RA101348 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is RA101495 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is SOBI002 (Swedish Orphan Biovitrum).
  • the C5 inhibitor is ARC1005 (Novo Nordisk). In one embodiment, the C5 inhibitor is a SOMAmer for C5 (SomaLogic). In one embodiment, the C5 inhibitor is SSL7. In one embodiment, the C5 inhibitor is MEDI7814 (MedImmune). In one embodiment, the C5 inhibitor is aurin tricarboxylic acid (Aurin Biotech). In another embodiment, the C5 inhibitor is an aurin tricarboxylic acid derivative (Aurin Biotech). In one embodiment, the C5 inhibitor is RG6107/SKY59 (Roche Pharmaceuticals). In one embodiment, the C5 inhibitor is ALXN1210 (Alexion Pharmaceuticals).
  • the C5 inhibitor is ALXN5500 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is TT30 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is ABP959 (Amgen). In one embodiment, the C5 inhibitor is Anti-C5 siRNA (Alnylam Pharmaceuticals). In one embodiment, the C5 inhibitor is Erdigna (Adienne Pharma). In one embodiment, the C5 inhibitor is avacincaptad pegol/Zimura® (Ophthotech). In one embodiment, the C5 inhibitor is SOBI005 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ISU305 (ISU ABXIS).
  • the C5 inhibitor is REGN3918 (Regeneron). In one embodiment, the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor.
  • the CFD inhibitor is Compound 1. In one embodiment, the CFD inhibitor is Compound 2. In one embodiment, the CFD inhibitor is Compound 3. In one embodiment, the CFD inhibitor is Compound 4. In one embodiment, the CFD inhibitor is Compound 5. In one embodiment, the CFD inhibitor is Compound 6. In one embodiment, the CFD inhibitor is Compound 7. In one embodiment, the CFD inhibitor is Compound 8. In one embodiment, the CFD inhibitor is Compound 9. In one embodiment, the CFD inhibitor is Compound 10. In one embodiment, the CFD inhibitor is Compound 11.
  • the CFD inhibitor is Compound 12. In one embodiment, the CFD inhibitor is Compound 13. In one embodiment, the CFD inhibitor is Compound 14. In one embodiment, the CFD inhibitor is Compound 15. In one embodiment, the CFD inhibitor is Compound 16. In one embodiment, the CFD inhibitor is Compound 17, In one embodiment, the CFD inhibitor is Compound 18. In one embodiment, the CFD inhibitor is
  • the CFD inhibitor is Compound 20. In one embodiment, the CFD inhibitor is Compound 21, In one embodiment, the CFD inhibitor is Compound 22. In one embodiment, the CFD inhibitor is Compound 23. In one embodiment, the CFD inhibitor is Compound 24. In one embodiment, the CFD inhibitor is Compound 25. In one embodiment, 100 mg of Compound 1 is administered three times a day. In one embodiment, 150 mg of Compound 1 is administered three times a day. In one embodiment, 200 mg of Compound 1 is administered three times a day.
  • a method of treating a subject with PNH comprising administering to the subject a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, wherein the subject at the time of administration of the CFD inhibitor has been on a therapeutic regimen comprising the administration of a C5 inhibitor, and wherein the subject at the time of administration of the CFD inhibitor has a hemoglobin level of less than about 12.0 g/dL.
  • the subject has a hemoglobin level of less than about 10.0 g/dL.
  • the subject has a hemoglobin level of less than about 8.0 g/dL.
  • the subject has an LDH level of greater than the upper limit of normal.
  • the subject has an LDH level of lesser than the upper limit of normal. In one embodiment, the subject has an LDH level of less than about 250 U/L. In one embodiment, the subject has an LDH level of greater than about 250 U/L. In one embodiment, the subject has an LDH level of greater than about 500 U/L.
  • the subject is blood transfusion dependent. In one embodiment, at the time of administration of the CFD inhibitor, the subject has received one or more blood transfusions within the prior twelve months. In one embodiment, the subject has had two or more blood transfusions within the prior six months. In one embodiment, the subject has had four or more blood transfusions within the prior six months.
  • the C5 inhibitor upon administration of the CFD inhibitor, the C5 inhibitor is no longer administered. In another particular embodiment, upon administration of the CFD inhibitor, the C5 inhibitor also continues to be administered.
  • the C5 inhibitor is a monoclonal antibody to C5. in one embodiment, the C5 inhibitor is eculizarnab. In one embodiment, the C5 inhibitor is a recombinant human minibody, for example Mubodina® (Adienne Pharma and Biotech). In one embodiment, the C5 inhibitor is coversin (Akari Therapeutics). In one embodiment, the C5 inhibitor is Tesidolumab/LFG316 (Novartis/Morphosys). In one embodiment, the C5 inhibitor is ARC-1905 (Ophthotech).
  • the C5 inhibitor is RA101348 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is RA101495 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is SOBI002 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ARC1005 (Novo Nordisk). In one embodiment, the C5 inhibitor is a SOMAmer for C5 (SomaLogic). In one embodiment, the C5 inhibitor is SSL7. In one embodiment, the C5 inhibitor is MEDI7814 (MedImmune). In one embodiment, the C5 inhibitor is aurin tricarboxylic acid (Aurin Biotech).
  • the C5 inhibitor is an aurin tricarboxylic acid derivative (Aurin Biotech). In one embodiment, the C5 inhibitor is RG6107/SKY59 (Roche Pharmaceuticals). In one embodiment, the C5 inhibitor is ALXN1210 (Alexion Pharmaceuticals). In another embodiment, the C5 inhibitor is ALXN5500 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is TT30 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is ABP959 (Amgen). In one embodiment, the C5 inhibitor is Anti-05 siRNA (Alnylam Pharmaceuticals). In one embodiment, the C5 inhibitor is Erdigna (Adienne Pharma).
  • the C5 inhibitor is avacincaptad pegol/Zimura® (Ophthotech). In one embodiment, the C5 inhibitor is SOBI005 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ISU305 (ISU ABXIS). In one embodiment, the C5 inhibitor is REGN3918 (Regeneron). In one embodiment, the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor. In one embodiment, the CFD inhibitor is Compound 1. In one embodiment, the CFD inhibitor is Compound 2. In one embodiment, the CFD inhibitor is Compound 3. In one embodiment, the CFD inhibitor is Compound 4. In one embodiment, the CFD inhibitor is Compound 5.
  • the CFD inhibitor is Compound 6. In one embodiment, the CFD inhibitor is Compound 7. In one embodiment, the CFD inhibitor is Compound 8. In one embodiment, the CFD inhibitor is Compound 9, In one embodiment, the CFD inhibitor is Compound 10, In one embodiment, the CFD inhibitor is Compound 11. In one embodiment, the CFD inhibitor is Compound 12. In one embodiment, the CFD inhibitor is Compound 13. In one embodiment, the CFD inhibitor is Compound 14. In one embodiment, the CFD inhibitor is Compound 15. In one embodiment, the CFD inhibitor is Compound 16. In one embodiment, the CFD inhibitor is Compound 17. In one embodiment, the CFD inhibitor is Compound 18. In one embodiment, the CFD inhibitor is Compound 19. In one embodiment, the CFD inhibitor is Compound 20.
  • the CFD inhibitor is Compound 21, In one embodiment, the CFD inhibitor is Compound 22. In one embodiment, the CFD inhibitor is Compound 23. In one embodiment, the CFD inhibitor is Compound 24. In one embodiment, the CFD inhibitor is Compound 25. In one embodiment, 100 mg of Compound 1 is administered three times a day. In one embodiment, 150 mg of Compound 1 is administered three times a day. In one embodiment, 200 mg of Compound 1 is administered three times a day.
  • a method of treating a subject with PNH comprising administering to the subject a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, wherein the subject at the time of administration of the CFD inhibitor has been on a therapeutic regimen comprising the administration of a C5 inhibitor, and wherein the subject at the time of administration of the CFD inhibitor has a hemoglobin level of less than about 12.0 g/dL and a LDH level of greater than about 250 U/L.
  • the subject has a hemoglobin level of less than about 10.0 g/dL.
  • the subject has a hemoglobin level of less than about 8.0 g/dL.
  • the subject is blood transfusion dependent. In one embodiment, at the time of administration of the CFD inhibitor, the subject has received one or more blood transfusions within the prior twelve months. In one embodiment, the subject has had two or more blood transfusions within the prior six months. In one embodiment, the subject has had four or more blood transfusions within the prior six months.
  • the C5 inhibitor upon administration of the CFD inhibitor, is no longer administered. In another particular embodiment, upon administration of the CFD inhibitor, the C5 inhibitor also continues to be administered. In a particular embodiment, the C5 inhibitor is a monoclonal antibody to C5. In one embodiment, the C5 inhibitor is eculizamab.
  • the C5 inhibitor is a recombinant human minibody, for example Mubodina® (Adienne Pharma and Biotech). In one embodiment, the C5 inhibitor is coversin (Akari Therapeutics). In one embodiment, the C5 inhibitor is Tesidolumab/LFG316 (Novartis/Morphosys). In one embodiment, the C5 inhibitor is ARC-1905 (Ophthotech). In one embodiment, the C5 inhibitor is RA101348 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is RA101495 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is SOBI002 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ARC1005 (Novo Nordisk).
  • the C5 inhibitor is a SOMAmer for C5 (SomaLogic). In one embodiment, the C5 inhibitor is SSL7. In one embodiment, the C5 inhibitor is MEDI7814 (MedImmune). In one embodiment, the C5 inhibitor is aurin tricarboxylic acid (Aurin Biotech). In another embodiment, the C5 inhibitor is an aurin tricarboxylic acid derivative (Aurin Biotech). In one embodiment, the C5 inhibitor is RG6107/SKY59 (Roche Pharmaceuticals). In one embodiment, the C5 inhibitor is ALXN1210 (Alexion Pharmaceuticals). In another embodiment, the C5 inhibitor is ALXN5500 (Alexion Pharmaceuticals).
  • the C5 inhibitor is TT30 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is ABP959 (Amgen). In one embodiment, the C5 inhibitor is Anti-05 siRNA (Alnylam Pharmaceuticals). In one embodiment, the C5 inhibitor is Erdigna (Adienne Pharma). In one embodiment, the C5 inhibitor is avacincaptad pegol/Zimura® (Ophthotech). In one embodiment, the C5 inhibitor is SOBI005 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ISU305 (ISU ABXIS). In one embodiment, the C5 inhibitor is REGN3918 (Regeneron).
  • the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor.
  • the CFD inhibitor is Compound 1. In one embodiment, the CFD inhibitor is Compound 2. In one embodiment, the CFD inhibitor is Compound 3. in one embodiment, the CFD inhibitor is Compound 4. In one embodiment, the CFD inhibitor is Compound 5. In one embodiment, the CFD inhibitor is Compound 6. In one embodiment, the CFD inhibitor is Compound 7, In one embodiment, the CFD inhibitor is Compound 8. In one embodiment, the CFD inhibitor is Compound 9. In one embodiment, the CFD inhibitor is Compound 10. in one embodiment, the CFD inhibitor is Compound 11. In one embodiment, the CFD inhibitor is Compound 12. In one embodiment, the CFD inhibitor is Compound 13.
  • the CFD inhibitor is Compound 14. In one embodiment, the CFD inhibitor is Compound 15. In one embodiment, the CFD inhibitor is Compound 16. In one embodiment, the CFD inhibitor is Compound 17. In one embodiment, the CFD inhibitor is Compound 18. In one embodiment, the CFD inhibitor is Compound 19. In one embodiment, the CFD inhibitor is Compound 20, In one embodiment, the CFD inhibitor is Compound 21. In one embodiment, the CM inhibitor is Compound 22. In one embodiment, the CH) inhibitor is Compound 23. In one embodiment, the CFD inhibitor is Compound 24. In one embodiment, the CFD inhibitor is Compound 25, In one embodiment. 100 mg of Compound 1 is administered three times a day. In one embodiment, 150 mg of Compound 1 is administered three times a day. In one embodiment, 200 mg of Compound 1 is administered three times a. day.
  • a method of treating a subject with PNH comprising administering to the subject a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, wherein the subject at the time of administration of the CFD inhibitor has been on a therapeutic regimen comprising the administration of a C5 inhibitor, and wherein the subject at the time of administration of the CFD inhibitor has a hemoglobin level of less than about 12.0 g/dL and a LDH level of greater than about 500 U/L.
  • the subject has a hemoglobin level of less than about 10.0 g/dL.
  • the subject has a hemoglobin level of less than about 8.0 g/dL.
  • the subject is blood transfusion dependent. In one embodiment, at the time of administration of the CFD inhibitor, the subject has received one or more blood transfusions within the prior twelve months. In one embodiment, the subject has two or more blood transfusions within the prior six months. In a particular embodiment, upon administration of the CFD inhibitor, the C5 inhibitor is no longer administered. In another particular embodiment, upon administration of the CFD inhibitor, the C5 inhibitor also continues to be administered. In a particular embodiment, the C5 inhibitor is a monoclonal antibody to C5. In one embodiment, the C5 inhibitor is eculizamab.
  • the C5 inhibitor is a recombinant human minibody, for example Mubodina® (Adienne Pharma and Biotech). In one embodiment, the C5 inhibitor is coversin (Akari Therapeutics). In one embodiment, the C5 inhibitor is Tesidolumab/LFG316 (Novartis/Morphosys). In one embodiment, the C5 inhibitor is ARC-1905 (Ophthotech). In one embodiment, the C5 inhibitor is RA101348 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is RA101495 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is SOBI002 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ARC1005 (Novo Nordisk).
  • the C5 inhibitor is a SOMAmer for C5 (SomaLogic). In one embodiment, the C5 inhibitor is SSL7. In one embodiment, the C5 inhibitor is MEDI7814 (MedImmune). In one embodiment, the C5 inhibitor is aurin tricarboxylic acid (Aurin Biotech). In another embodiment, the C5 inhibitor is an aurin tricarboxylic acid derivative (Aurin Biotech). In one embodiment, the C5 inhibitor is RG6107/SKY59 (Roche Pharmaceuticals). In one embodiment, the C5 inhibitor is ALXN1210 (Alexion Pharmaceuticals). In another embodiment, the C5 inhibitor is ALXN5500 (Alexion Pharmaceuticals).
  • the C5 inhibitor is TT30 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is ABP959 (Amgen). In one embodiment, the C5 inhibitor is Anti-05 siRNA (Alnylam Pharmaceuticals). In one embodiment, the C5 inhibitor is Erdigna (Adienne Pharma). In one embodiment, the C5 inhibitor is avacincaptad pegol/Zimura® (Ophthotech). In one embodiment, the C5 inhibitor is SOBI005 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ISU305 (ISU ABXIS). In one embodiment, the C5 inhibitor is REGN3918 (Regeneron).
  • the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor.
  • the CFD inhibitor is Compound 1. In one embodiment, the CFD inhibitor is Compound 2. In one embodiment, the CFD inhibitor is Compound 3. In one embodiment, the CFD inhibitor is Compound 4. In one embodiment, the CFD inhibitor is Compound 5. In one embodiment. the CFD inhibitor is Compound 6. In one embodiment, the CFD inhibitor is Compound 7. In one embodiment, the CFD inhibitor is Compound 8. In one embodiment, the CFD inhibitor is Compound 9. In one embodiment, the CFD inhibitor is Compound 10. In one embodiment, the CFD inhibitor is Compound 11. In one embodiment, the CFD inhibitor is Compound 12.
  • the CFD inhibitor is Compound 13, In one embodiment, the CFD inhibitor is Compound 14, In one embodiment, the CFD inhibitor is Compound 15. In one embodiment, the CFD inhibitor is Compound 16. In one embodiment, the CFD inhibitor is Compound 17. In one embodiment, the CFD inhibitor is Compound 18. In one embodiment, the CFD inhibitor is Compound 19. In one embodiment, the CFD inhibitor is Compound 20, In one embodiment, the CFD inhibitor is Compound 21. In one embodiment, the CFD inhibitor is Compound 22. In one embodiment, the CFD inhibitor is Compound 23. In one embodiment, the CFD inhibitor is Compound 24. In one embodiment, the CFD inhibitor is Compound 25. In one embodiment, 100 mg of Compound 1 is administered three times a day. In one embodiment, 150 mg of Compound 1 is administered three times a day. In one embodiment, 200 mg of Compound 1 is administered three times a day.
  • a method of treating a subject with PNH comprising administering to the subject a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, wherein the subject at the time of administration of the CFD inhibitor has been on a therapeutic regimen comprising the administration of a C5 inhibitor, and wherein the subject at the time of administration of the CFD inhibitor has a hemoglobin level of less than about 12.0 g/dL and a LDH level of less than about 250 U/L.
  • the subject has a hemoglobin level of less than about 10.0 g/dL.
  • the subject has a hemoglobin level of less than about 8.0 g/dL.
  • the subject is blood transfusion dependent. In one embodiment, at the time of administration of the CFD inhibitor, the subject has received one or more blood transfusions within the prior twelve months. In one embodiment, the subject has had two or more blood transfusions within the prior six months. In one embodiment, the subject has had found or more blood transfusions within the prior six months.
  • the C5 inhibitor upon administration of the CFD inhibitor, is no longer administered. In another particular embodiment, upon administration of the CFD inhibitor, the C5 inhibitor also continues to be administered. In a particular embodiment, the C5 inhibitor is a monoclonal antibody to C5. In one embodiment, the C5 inhibitor is eculizarnab.
  • the C5 inhibitor is a recombinant human minibody, for example Mubodina® (Adienne Pharma and Biotech). In one embodiment, the C5 inhibitor is coversin (Akari Therapeutics). In one embodiment, the C5 inhibitor is Tesidolumab/LFG316 (Novartis/Morphosys). In one embodiment, the C5 inhibitor is ARC-1905 (Ophthotech). In one embodiment, the C5 inhibitor is RA101348 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is RA101495 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is SOBI002 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ARC1005 (Novo Nordisk).
  • the C5 inhibitor is a SOMAmer for C5 (SomaLogic). In one embodiment, the C5 inhibitor is SSL7. In one embodiment, the C5 inhibitor is MEDI7814 (MedImmune). In one embodiment, the C5 inhibitor is aurin tricarboxylic acid (Aurin Biotech). In another embodiment, the C5 inhibitor is an aurin tricarboxylic acid derivative (Aurin Biotech). In one embodiment, the C5 inhibitor is RG6107/SKY59 (Roche Pharmaceuticals). In one embodiment, the C5 inhibitor is ALXN1210 (Alexion Pharmaceuticals). In another embodiment, the C5 inhibitor is ALXN5500 (Alexion Pharmaceuticals).
  • the C5 inhibitor is TT30 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is ABP959 (Amgen). In one embodiment, the C5 inhibitor is Anti-05 siRNA (Alnylam Pharmaceuticals). In one embodiment, the C5 inhibitor is Erdigna (Adienne Pharma). In one embodiment, the C5 inhibitor is avacincaptad pegol/Zimura® (Ophthotech). In one embodiment, the C5 inhibitor is SOBI005 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ISU305 (ISU ABXIS). In one embodiment, the C5 inhibitor is REGN3918 (Regeneron).
  • the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor.
  • the CFD inhibitor is Compound 1. In one embodiment, the CFD inhibitor is Compound 2. In one embodiment, the CFD inhibitor is Compound 3. In one embodiment, the CFD inhibitor is Compound 4. In one embodiment, the CFD inhibitor is Compound 5. In one embodiment, the CFD inhibitor is Compound 6. In one embodiment, the CFD inhibitor is Compound 7. In one embodiment, the CFD inhibitor is Compound 1. In one embodiment, the CFD inhibitor is Compound 1. In one embodiment, the CFD inhibitor is Compound 2. In one embodiment, the CFD inhibitor is Compound 3. In one embodiment, the CFD inhibitor is Compound 4. In one embodiment, the CFD inhibitor is Compound 5. In one embodiment, the CFD inhibitor is Compound 6. In one embodiment, the CFD inhibitor is Compound 7. In one embodiment, the CFD inhibitor is
  • the CFD inhibitor is Compound 9. In one embodiment, the CFD inhibitor is Compound 10, In one embodiment, the CFD inhibitor is Compound 11. In one embodiment, the CFD inhibitor is Compound 12. In one embodiment, the CFD inhibitor is Compound 13. In one embodiment, the CFD inhibitor is Compound 14. In one embodiment, the CFD inhibitor is Compound 15. In one embodiment, the CFD inhibitor is Compound 16. In one embodiment, the CFD inhibitor is Compound 17. In one embodiment, the CFD inhibitor is Compound 18. In one embodiment, the CFD inhibitor is Compound 19. In one embodiment, the CFD inhibitor is Compound 20. In one embodiment, the CFD inhibitor is Compound 21, In one embodiment, the CFD inhibitor is Compound 22. In one embodiment, the CFD inhibitor is Compound 23.
  • the CFD inhibitor is Compound 24. In one embodiment, the CFD inhibitor is Compound 25. In one embodiment, 100 mg of Compound 1 is administered three times a day. In one embodiment, 150 mg of Compound 1 is administered three times a day. In one embodiment, 200 mg of Compound 1 is administered three times a day.
  • a method of treating a subject with PNH comprising administering to the subject a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, wherein the subject at the time of administration of the CFD inhibitor has been on a therapeutic regimen comprising the administration of a C5 inhibitor, and wherein the subject at the time of administration of the CFD inhibitor has a positive direct Coombs test.
  • the subject has a hemoglobin level of less than about 12 g/dL. In one embodiment, the subject has a hemoglobin level of less than about 10 g/dL. In one embodiment, the subject has a hemoglobin level of less than about 8 g/dL.
  • the subject has an LDH level that is greater than the upper limit of normal. In one embodiment, the subject has an LDH level that is less than the upper limit or normal. In one embodiment, the subject has an LDH level of less than about 250 U/L. In one embodiment, the subject has an LDH level of greater than about 250 U/L. In one embodiment, the subject has an LDH level of greater than about 500 U/L.
  • the subject is blood transfusion dependent. In one embodiment, at the time of administration of the CFD inhibitor, the subject has received one or more blood transfusions within the prior twelve months. In one embodiment, the subject has two or more blood transfusions within the prior six months. In a.
  • the C5 inhibitor upon administration of the CFD inhibitor, the C5 inhibitor is no longer administered. in another particular embodiment, upon administration of the CFD inhibitor, the C5 inhibitor also continues to be administered.
  • the C5 inhibitor is a. monoclonal antibody to C5.
  • the C5 inhibitor is eculizamab.
  • the C5 inhibitor is a recombinant human minibody, for example Mubodina® (Adienne Pharma and Biotech).
  • the C5 inhibitor is coversin (Akari Therapeutics).
  • the C5 inhibitor is Tesidolumab/LFG316 (Novartis/Morphosys).
  • the C5 inhibitor is ARC-1905 (Ophthotech).
  • the C5 inhibitor is RA101348 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is RA101495 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is SOBI002 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ARC1005 (Novo Nordisk). In one embodiment, the C5 inhibitor is a SOMAmer for C5 (SomaLogic). In one embodiment, the C5 inhibitor is SSL7. In one embodiment, the C5 inhibitor is MEDI7814 (MedImmune). In one embodiment, the C5 inhibitor is aurin tricarboxylic acid (Aurin Biotech).
  • the C5 inhibitor is an aurin tricarboxylic acid derivative (Aurin Biotech). In one embodiment, the C5 inhibitor is RG6107/SKY59 (Roche Pharmaceuticals). In one embodiment, the C5 inhibitor is ALXN1210 (Alexion Pharmaceuticals). In another embodiment, the C5 inhibitor is ALXN5500 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is TT30 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is ABP959 (Amgen). In one embodiment, the C5 inhibitor is Anti-05 siRNA (Alnylam Pharmaceuticals). In one embodiment, the C5 inhibitor is Erdigna (Adienne Pharma).
  • the C5 inhibitor is avacincaptad pegol/Zimura® (Ophthotech). In one embodiment, the C5 inhibitor is SOBI005 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ISU305 (ISU ABXIS). In one embodiment, the C5 inhibitor is REGN3918 (Regeneron). In one embodiment, the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor. In one embodiment, the CFD inhibitor is Compound 1, In one embodiment, the CFI) inhibitor is Compound 2. In one embodiment, the CFD inhibitor is Compound 3. In one embodiment, the CFD inhibitor is Compound 4. In one embodiment, the CFD inhibitor is Compound 5.
  • the CFD inhibitor is Compound 6. In one embodiment, the CFD inhibitor is Compound 7. In one embodiment. the CFD inhibitor is Compound 8. In one embodiment, the CFD inhibitor is Compound 9. In one embodiment, the CFD inhibitor is Compound 10. In one embodiment, the CFD inhibitor is Compound 11. In one embodiment, the CFD inhibitor is Compound 12. In one embodiment, the CFD inhibitor is Compound 13. In one embodiment, the CFD inhibitor is Compound 14. In one embodiment, the CFD inhibitor is Compound 15. In one embodiment, the CFD inhibitor is Compound 16. In one embodiment, the CFD inhibitor is Compound 17. In one embodiment, the CFD inhibitor is Compound 18. In one embodiment, the CFD inhibitor is Compound 19. In one embodiment, the CFD inhibitor is Compound 20.
  • the CFD inhibitor is Compound 21. In one embodiment, the CFD inhibitor is Compound 22, In one embodiment, the CFD inhibitor is Compound 23. In one embodiment, the CFD inhibitor is Compound 24. In one embodiment, the CFD inhibitor is Compound 25. In one embodiment, 100 mg of Compound 1 is administered three times a day. In one embodiment, 150 mg of Compound 1 is administered three times a day. In one embodiment, 200 mg of Compound 1 is administered three times a day.
  • a method of treating a subject with PNH comprising administering to the subject a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, wherein the subject at the time of administration of the CFD inhibitor has been on a therapeutic regimen comprising the administration of a C5 inhibitor, and wherein the subject at the time of administration of the C5 inhibitor shows C 3 fragment deposition.
  • the subject has a hemoglobin level of less than about 10 g/dL.
  • the subject has a hemoglobin level of less than about 8 g/dL.
  • the subject has an LDH level that is greater than the upper limit of normal.
  • the subject has an LDH level that is less than the upper limit or normal. In one embodiment, the subject has an LDH level of less than about 250 U/L. In one embodiment, the subject has an LDH level of greater than about 250 U/L. In one embodiment, the subject has an LDH level of greater than about 500 U/L.
  • the subject is blood transfusion dependent. In one embodiment, at the time of administration of the CFD inhibitor, the subject has received one or more blood transfusions within the prior twelve months. In one embodiment, the subject has two or more blood transfusions within the prior six months. In a particular embodiment, upon administration of the CFD inhibitor, the C5 inhibitor is no longer administered.
  • the C5 inhibitor upon administration of the CFD inhibitor, the C5 inhibitor also continues to be administered.
  • the C5 inhibitor is a monoclonal antibody to C5.
  • the C5 inhibitor is eculizarnab.
  • the C5 inhibitor is a recombinant human minibody, for example Mubodina® (Adienne Pharma and Biotech).
  • the C5 inhibitor is coversin (Akari Therapeutics).
  • the C5 inhibitor is Tesidolumab/LFG316 (Novartis/Morphosys).
  • the C5 inhibitor is ARC-1905 (Ophthotech).
  • the C5 inhibitor is RA101348 (Ra Pharmaceuticals).
  • the C5 inhibitor is RA101495 (Ra Pharmaceuticals). In one embodiment, the C5 inhibitor is SOBI002 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ARC1005 (Novo Nordisk). In one embodiment, the C5 inhibitor is a SOMAmer for C5 (SomaLogic). In one embodiment, the C5 inhibitor is SSL7. In one embodiment, the C5 inhibitor is MEDI7814 (MedImmune). In one embodiment, the C5 inhibitor is aurin tricarboxylic acid (Aurin Biotech). In another embodiment, the C5 inhibitor is an aurin tricarboxylic acid derivative (Aurin Biotech).
  • the C5 inhibitor is RG6107/SKY59 (Roche Pharmaceuticals). In one embodiment, the C5 inhibitor is ALXN1210 (Alexion Pharmaceuticals). In another embodiment, the C5 inhibitor is ALXN5500 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is TT30 (Alexion Pharmaceuticals). In one embodiment, the C5 inhibitor is ABP959 (Amgen). In one embodiment, the C5 inhibitor is Anti-C5 siRNA (Alnylam Pharmaceuticals). In one embodiment, the C5 inhibitor is Erdigna (Adienne Pharma). In one embodiment, the C5 inhibitor is avacincaptad pegol/Zimura® (Ophthotech).
  • the C5 inhibitor is SOBI005 (Swedish Orphan Biovitrum). In one embodiment, the C5 inhibitor is ISU305 (ISU ABXIS). In one embodiment, the C5 inhibitor is REGN3918 (Regeneron). In one embodiment, the subject has been on a C5 therapeutic regimen for at least 3-months prior to administration of the CFD inhibitor. In one embodiment, the CFD inhibitor is Compound 1. In one embodiment, the CFD inhibitor is Compound 2. In one embodiment, the CFD inhibitor is Compound 3. In one embodiment, the CFD inhibitor is Compound 4. In one embodiment, the CFD inhibitor is Compound 5. In one embodiment, the CFD inhibitor is Compound 6, In one embodiment, the CFD inhibitor is Compound 7. In one embodiment, the CFD inhibitor is Compound 8.
  • the CFD inhibitor is Compound 9. In one embodiment, the CFD inhibitor is Compound 10. in one embodiment, the CFD inhibitor is Compound 11. In one embodiment, the CFD inhibitor is Compound 12. In one embodiment, the CFD inhibitor is Compound 13. In one embodiment, the CFD inhibitor is Compound 14. In one embodiment, the CFD inhibitor is Compound 15. In one embodiment, the CFD inhibitor is Compound 16. In one embodiment, the CFD inhibitor is Compound 17. In one embodiment, the CFD inhibitor is Compound 18, In one embodiment, the CFD inhibitor is Compound 19. In one embodiment, the CFD inhibitor is Compound 20. In one embodiment, the CFD inhibitor is Compound 21. In one embodiment, the CFD inhibitor is Compound 22, In one embodiment, the CFD inhibitor is Compound 23.
  • the CFD inhibitor is Compound 24. In one embodiment, the CFD inhibitor is Compound 25. In one embodiment, 100 mg of Compound 1 is administered three times a day. In one embodiment, 150 mg of Compound 1 is administered three times a day. In one embodiment, 200 mg of Compound 1 is administered three times a. day.
  • a method of treating a subject with PNH comprising:
  • the development of extravascular hemolysis can be detected, and the subject administered a CFD inhibitor selected from Formula I and Formula II.
  • the subject experiencing extravascular hemolysis is also experiencing intravascular hemolysis.
  • a method of treating a subject with PNH comprising
  • a CFD inhibitor selected from Formula I or Formula II.
  • PNH subjects suffering from residual or recurrent intravascular hemolysis may have increasing levels of LDH over time, for example greater than or equal to 1.5 ⁇ ULN (upper limit of normal) for LDH.
  • PNH subjects with residual intravascular hemolysis may have decreased levels of hemoglobin in their serum.
  • a PNH subject receiving a C5 inhibitor is further administered a CFD inhibitor described herein when their serum hemoglobin level is below about 7 g/dL.
  • a PNH subject receiving a C5 inhibitor is further administered a CFD inhibitor described herein when their serum hemoglobin level below about 8 g/dL.
  • a PNH subject receiving a C5 inhibitor is further administered a CFD inhibitor described herein when their serum hemoglobin level is below about 9 g/dL. In one embodiment, a PNH subject receiving a C5 inhibitor is further administered a CFD inhibitor described herein when their serum hemoglobin level is below about 10 g/dL. In one embodiment, a PNH subject receiving a C5 inhibitor is further administered a CFD inhibitor described herein when their serum hemoglobin level is below about 15, 14, 13, 12, or 11 g/dL. In an alternative embodiment, the PNH subject is administered an CFD inhibitor upon receiving 4 units of blood in a transfusion within about a 6-month period of time.
  • the subject is administered a CFD inhibitor if they have a hemoglobin level of below about 10 g/dL and a LDH level of about 140 units per liter (U/L) to 280 U/L following treatment with a C5 inhibitor.
  • the subject is administered a CFD inhibitor if they have a hemoglobin level of below about 15, 14, 13, 12, or 11 g/dL and a LDH level of about 140 units per liter (U/L) to 280 U/L following treatment with a C5 inhibitor.
  • the subject is administered a CFD inhibitor if they have a transfusion dependence of about 4 units in 6 months and a LDH level of about 140 units per liter (U/L) to 280 U/L following treatment with a C5 inhibitor.
  • a method wherein a subject with PNH with an LDH level greater than or equal to 1.5 ⁇ ULN (upper limit for normal) for LDH is administered a therapeutically effective amount of a C5 inhibitor and the subject's LDH level decreases, but the subject still has continued anemia as indicated by low hemoglobin levels and/or high transfusion dependence, and the subject is administered a therapeutically effective amount of a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically salt thereof.
  • a CFD inhibitor selected from a compound of Formula I or Formula II, or a pharmaceutically salt thereof.
  • hemoglobin levels involve standard clinical chemistry protocols that would be known to those of skill in the art.
  • One non-limiting example of a. commercially available hemoglobin assay involves reaction of hemoglobin with Triton and sodium hydroxide to form a colorimetric product that is measurable at 400 nm. This assay can measure hemoglobin levels from 0.9 to 200 mg/dl.
  • commercially available hemoglobinometers can measure hemoglobin levels by spectrophotometric analysis. Normal hemoglobin levels are considered to be from about 13.5 to about 17.5 g/dL for men and from about 12.0 to about 15.5 g/dL for women. A patient is considered anemic if their hemoglobin levels fall below about 10.0 g/dL.
  • LDH levels involve standard clinical chemistry protocols that would be known to those of skill in the art.
  • One non-limiting example of a commercially available assay involves reaction of free LDH with NAD to form NADH, the formed NADH then interacting with a chemical probe to form a colorimetric product that is measurable at 450 nm.
  • This assay can measure LDH levels from 1 to 100 U/L. Normal LDH levels are considered to be less than about 250 U/L, while LDH levels are considered elevated when greater than about 250 U/L. LDH levels are considered highly elevated when greater than about 500 U/L.
  • the direct Coombs test is a clinical blood test used to detect antibodies or complement proteins bound to the surface of red blood cells that would be known to those of skill in the art.
  • a blood sample is taken and the red blood cells (RBCs) are washed to remove the patient's own plasma.
  • the RBCs are then incubated with anti-human globulin (“Coombs reagent”). If agglutination of the RBCs occurs, then the direct Coombs test is positive, indicative of the presence of antibodies or complement proteins bound to the surface of the RBCs.
  • C3 fragment deposition is measured using blood by flow cytometry that would be known to those of skill in the art.
  • a blood sample is collected from eculizumab-treated PNH patients or healthy individuals. Erythrocytes are harvested by centrifugation, washed with PBS several times until the supernatant remains clear.
  • C3 fragment deposition on the PNH erythrocytes membrane is measured by flow cytometry using FITC-conjugated anti-C3c, PE conjugated anti-CD47 and APC-conjugated anti-CD59 following dilution of reaction mixtures in FC buffer. Intact and fragmented PNH erythrocytes are identified by anti-CD47 (positive) and anti-CD59 (negative) staining.
  • C3 fragment deposition is assessed by anti-C3c staining.
  • Also provided herein is a method of treating a subject with PNH comprising administering to the subject a therapeutically effective amount of a CFD inhibitor selected from Formula I or Formula II in combination with a C3 inhibitor.
  • a CFD inhibitor selected from Formula I or Formula II in combination with a complement component C3 inhibitor also provides for synergistic inhibition of hemolysis of PNH erythrocytes. These synergistic effects provide for increased therapeutic efficacy in the treatment of PNH, while reducing the required amount of inhibitor necessary for therapeutic efficacy.
  • the C3 inhibitor is selected from compstatin or a compstatin analog or derivative.
  • the C3 inhibitor is compstatin.
  • the C3 inhibitor is the compstatin analog 4(1MeW)/APL-1.
  • the C3 inhibitor is the compstatin analog CP-40.
  • the C3 inhibitor is the compstatin analog Peg-CP-40. 4(1MeW), CP40/AMY-101, and Peg-CP-40 are described in Risitano, Ricklin et al., Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria, Blood. 2014 Mar. 27; 123(13):2094-101, incorporated herein by reference.
  • the C3 inhibitor is AMY-201 (Amyndas Pharmaceuticals). In a particular embodiment, the C3 inhibitor is APL-2 (Apellis Pharmaceuticals). In a particular embodiment, the C3 inhibitor is ATA (aurin tricarboxylic acid) (Aurin Biotech, US Pat Appl Pub US20130035392, incorporated herein by reference).
  • a method of treating a subject with PNH comprising administering to the subject a therapeutically effective amount of a CFD inhibitor selected from Formula I or Formula II in combination with a complement factor B inhibitor.
  • a CFD inhibitor selected from Formula I or Formula II in combination with a complement factor B inhibitor.
  • the CFB inhibitor is LNP023 (Novartis).
  • the CFB inhibitor is selected from an inhibitor described in WO2013/192345, incorporated by reference herein.
  • the CFB inhibitor is
  • the CFB inhibitor is selected from an inhibitor described in International Application No. PCT/US17/39587, incorporated herein by reference.
  • a method of treating a subject with PNH comprising administering to the subject a therapeutically effective amount of a CFD inhibitor selected from Formula I or Formula II in combination with a pan-inhibitor to complement components.
  • the inhibitor is FUT-175.
  • Compound 1 can be administered once a day, twice a day, or three times a day. In some embodiments, Compound 1 can be administered in a 100 mg, 150 mg, or 200 mg dose. In one embodiment, Compound 1 is administered in a 100 mg dose three times a day. In one embodiment, Compound 1 is administered in a 150 mg dose three times a day. In one embodiment, Compound 1 is administered in a 200 mg dose three times a day. In particular embodiments, 100 mg of Compound 1 is administered three times a day in combination or alternation with a C5 inhibitor. In particular embodiments, 150 mg of Compound 1 is administered three times a day in combination or alternation with a C5 inhibitor.
  • 200 mg of Compound 1 is administered three times a day in combination or alternation with C5 inhibitor.
  • 100 mg of Compound 1 is administered three times a day in combination or alternation with eculizamab.
  • 150 mg of Compound 1 is administered three times a day in combination or alternation with eculizamab.
  • 200 mg of Compound 1 is administered three times a day in combination or alternation with eculizamab.
  • a CFD inhibitor described herein, or its salt, isotopic analog, or prodrug can be administered in an effective amount to a host to treat any of the disorders described herein using any suitable approach which achieves the desired therapeutic result.
  • the amount and timing of active compound administered will, of course, be dependent on the host being treated, the instructions of the supervising medical specialist, on the time course of the exposure, on the manner of administration, on the pharmacokinetic properties of the particular active compound, and on the judgment of the prescribing physician.
  • the dosages given below are a guideline and the physician can titrate doses of the compound to achieve the treatment that the physician considers appropriate for the host.
  • the physician can balance a variety of factors such as age and weight of the host, presence of preexisting disease, as well as presence of other diseases.
  • the pharmaceutical composition may be formulated as any pharmaceutically useful form, e.g., as an aerosol, a cream, a gel, a pill, an injection or infusion solution, a capsule, a tablet, a syrup, a transdermal patch, a subcutaneous patch, a dry powder, an inhalation formulation, in a medical device, suppository, buccal, or sublingual formulation, parenteral formulation, or an ophthalmic solution.
  • Some dosage forms, such as tablets and capsules are subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.
  • the therapeutically effective dosage of any active compound described herein will be determined by the health care practitioner depending on the condition, size and age of the subject as well as the route of delivery.
  • a dosage from about 0.1 to about 200 mg/kg has therapeutic efficacy, with all weights being calculated based upon the weight of the active compound, including the cases where a salt is employed.
  • the dosage is at about or greater than 0.1, 0.5, 1, 5, 10, 25, 50, 75, 100, 125, 150, 175, or 200 mg/kg.
  • the dosage may be the amount of compound needed to provide a serum concentration of the active compound of up to about 10 nM, 50 nM, 100 nM, 200 nM, 300 nM, 400 nM, 500 nM, 600 nM, 700 nM, 800 nM, 900 nM, 1 ⁇ M, 5 ⁇ M, 10 ⁇ M, 20 ⁇ M, 30 ⁇ M, or 40 ⁇ M.
  • the pharmaceutical composition is in a dosage form that contains from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of the active compound and optionally from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of an additional active agent in a unit dosage form.
  • Examples include dosage forms with at least 5, 10, 15, 20, 25, 50, 100, 200, 250, 300, 400, 500, 600, 700, or 750 mg of active compound, or its salt.
  • the pharmaceutical composition may also include a molar ratio of the active compound and an additional active agent, in a ratio that achieves the desired results.
  • Compounds disclosed herein or used as described herein may be administered orally, topically, parenterally, by inhalation or spray, sublingually, via implant, including ocular implant, transdermally, via buccal administration, rectally, as an ophthalmic solution, injection, including ocular injection, intravenous, intramuscular, inhalation, intra-aortal, intracranial, subdermal, intraperitoneal, subcutaneous, transnasal, sublingual, or rectal or by other means, in dosage unit formulations containing conventional pharmaceutically acceptable carriers.
  • the compound can be administered, as desired, for example, via intravitreal, intrastromal, intracameral, sub-tenon, sub-retinal, retro-bulbar, peribulbar, suprachorodial, conjunctival, subconjunctival, epi scleral, periocular, transscleral, retrobulbar, posterior juxtascleral, circumcorneal, or tear duct injections, or through a mucus, mucin, or a mucosal barrier, in an immediate or controlled release fashion or via an ocular device.
  • an oral administration can be in any desired form such as a solid, gel or liquid, including a solution, suspension, or emulsion.
  • the compounds or salts are administered by inhalation, intravenously, or intramuscularly as a liposomal suspension.
  • the active compound or salt may be in the form of a plurality of solid particles or droplets having any desired particle size, and for example, from about 0.01, 0.1 or 0.5 to about 5, 10, 20 or more microns, and optionally from about 1 to about 2 microns.
  • Compounds as disclosed in the present invention have demonstrated good pharmacokinetic and pharmacodynamics properties, for instance when administered by the oral or intravenous routes.
  • the pharmaceutical formulations can comprise an active compound described herein or a pharmaceutically acceptable salt thereof, in any pharmaceutically acceptable carrier.
  • water may sometimes be the carrier of choice for water-soluble compounds or salts.
  • an organic vehicle such as glycerol, propylene glycol, polyethylene glycol, or mixtures thereof, can be suitable. In the latter instance, the organic vehicle can contain a substantial amount of water.
  • the solution in either instance can then be sterilized in a suitable manner known to those in the art, and for illustration by filtration through a 0.22-micron filter. Subsequent to sterilization, the solution can be dispensed into appropriate receptacles, such as depyrogenated glass vials. The dispensing is optionally done by an aseptic method. Sterilized closures can then be placed on the vials and, if desired, the vial contents can be lyophilized.
  • Carriers include excipients and diluents and must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the subject being treated.
  • the carrier can be inert or it can possess pharmaceutical benefits of its own.
  • the amount of carrier employed in conjunction with the Compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.
  • Classes of carriers include, but are not limited to binders, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, flavorants, glidents, lubricants, preservatives, stabilizers, surfactants, tableting agents, and wetting agents.
  • Some carriers may be listed in more than one class, for example vegetable oil may be used as a lubricant in some formulations and a diluent in others.
  • Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin; talc, and vegetable oils.
  • Optional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of the present invention.
  • a biological buffer can be any solution which is pharmacologically acceptable and which provides the formulation with the desired pH, i.e., a pH in the physiologically acceptable range.
  • buffer solutions include saline, phosphate buffered saline, Tris buffered saline, Hank's buffered saline, and the like.
  • the pharmaceutical compositions can be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, creams, ointments, lotions or the like, preferably in unit dosage form suitable for single administration of a precise dosage.
  • the compositions will include an effective amount of the selected drug in combination with a pharmaceutically acceptable carrier and, in addition, can include other pharmaceutical agents, adjuvants, diluents, buffers, and the like.
  • compositions of the disclosure can be administered as pharmaceutical formulations including those suitable for oral (including buccal and sub-lingual), rectal, nasal, topical, pulmonary, vaginal or parenteral (including intramuscular, intra-arterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
  • oral including buccal and sub-lingual
  • rectal including nasal, topical, pulmonary, vaginal or parenteral (including intramuscular, intra-arterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
  • parenteral including intramuscular, intra-arterial, intrathecal, subcutaneous and intravenous administration or in a form suitable for administration by inhalation or insufflation.
  • the preferred manner of administration is intravenous or oral using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.
  • conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like.
  • Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, and the like, an active compound as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
  • the pharmaceutical composition to be administered can also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and the like.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and the like.
  • permeation enhancer excipients including polymers such as: polycations (chitosan and its quaternary ammonium derivatives, poly-L-arginine, aminated gelatin); polyanions (N-carboxymethyl chitosan, poly-acrylic acid); and, thiolated polymers (carboxymethyl cellulose-cysteine, polycarbophil-cysteine, chitosan-thiobutylamidine, chitosan-thioglycolic acid, chitosan-glutathione conjugates).
  • polycations chitosan and its quaternary ammonium derivatives, poly-L-arginine, aminated gelatin
  • polyanions N-carboxymethyl chitosan, poly-acrylic acid
  • thiolated polymers carboxymethyl cellulose-cysteine, polycarbophil-cysteine, chitosan-thiobutylamidine, chitosan-thioglycoli
  • the composition will generally take the form of a tablet, capsule, a softgel capsule or can be an aqueous or nonaqueous solution, suspension or syrup. Tablets and capsules are preferred oral administration forms. Tablets and capsules for oral use can include one or more commonly used carriers such as lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added.
  • the compositions of the disclosure can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like.
  • suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
  • the active agent can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like and with emulsifying and suspending agents. If desired, flavoring, coloring and/or sweetening agents can be added as well.
  • suitable inert carrier such as ethanol, glycerol, water, and the like
  • flavoring, coloring and/or sweetening agents can be added as well.
  • Other optional components for incorporation into an oral formulation herein include, but are not limited to, preservatives, suspending agents, thickening agents, and the like.
  • Parenteral formulations can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solubilization or suspension in liquid prior to injection, or as emulsions.
  • sterile injectable suspensions are formulated according to techniques known in the art using suitable carriers, dispersing or wetting agents and suspending agents.
  • the sterile injectable formulation can also be a sterile injectable solution or a suspension in a nontoxic parenterally acceptable diluent or solvent.
  • the acceptable vehicles and solvents that can be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils, fatty esters or polyols are conventionally employed as solvents or suspending media.
  • parenteral administration can involve the use of a slow release or sustained release system such that a constant level of dosage is maintained.
  • Parenteral administration includes intraarticular, intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, and include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • aqueous and non-aqueous, isotonic sterile injection solutions which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient
  • aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • Administration via certain parenteral routes can involve introducing the formulations of the disclosure into the body of a subject through a needle or a catheter, propelled by a sterile syringe or some other mechanical device such as a continuous infusion system.
  • a formulation provided by the disclosure can be administered using a syringe, injector, pump, or any other device recognized in the art for parenteral administration.
  • the pharmaceutical formulations can contain other additives, such as pH-adjusting additives.
  • useful pH-adjusting agents include acids, such as hydrochloric acid, bases or buffers, such as sodium lactate, sodium acetate, sodium phosphate, sodium citrate, sodium borate, or sodium gluconate.
  • the formulations can contain antimicrobial preservatives.
  • Useful antimicrobial preservatives include methylparaben, propylparaben, and benzyl alcohol. An antimicrobial preservative is typically employed when the formulations is placed in a vial designed for multi-dose use.
  • the pharmaceutical formulations described herein can be lyophilized using techniques well known in the art.
  • a pharmaceutical composition can take the form of a solution suspension, tablet, pill, capsule, powder, and the like.
  • Tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch (e.g., potato or tapioca starch) and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate, and talc are often very useful for tableting purposes.
  • Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules.
  • compositions in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • the compounds of the presently disclosed host matter can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • injectable, stable, sterile formulations comprising an active compound as described herein, or a salt thereof, in a unit dosage form in a sealed container.
  • the compound or salt is provided in the form of a lyophilizate, which is capable of being reconstituted with a suitable pharmaceutically acceptable carrier to form liquid formulation suitable for injection thereof into a host.
  • a sufficient amount of emulsifying agent which is physiologically acceptable, can be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier.
  • Particularly useful emulsifying agents include phosphatidyl cholines and lecithin.
  • Additional embodiments provided herein include liposomal formulations of the active compounds disclosed herein.
  • the technology for forming liposomal suspensions is well known in the art.
  • the Compound 1 is an aqueous-soluble salt, using conventional liposome technology, the same can be incorporated into lipid vesicles.
  • the active compound due to the water solubility of the active compound, the active compound can be substantially entrained within the hydrophilic center or core of the liposomes.
  • the lipid layer employed can be of any conventional composition and can either contain cholesterol or can be cholesterol-free.
  • the active compound of interest is water-insoluble, again employing conventional liposome formation technology, the salt can be substantially entrained within the hydrophobic lipid bilayer that forms the structure of the liposome.
  • the liposomes that are produced can be reduced in size, as through the use of standard sonication and homogenization techniques.
  • the liposomal formulations comprising the active compounds disclosed herein can be lyophilized to produce a lyophilizate, which can be reconstituted with a pharmaceutically acceptable carrier, such as water, to regenerate a liposomal suspension.
  • compositions which are suitable for administration as an aerosol by inhalation. These formulations comprise a solution or suspension of a desired compound described herein or a salt thereof, or a plurality of solid particles of the compound or salt.
  • the desired formulations can be placed in a small chamber and nebulized. Nebulization can be accomplished by compressed air or by ultrasonic energy to form a plurality of liquid droplets or solid particles comprising the compounds or salts.
  • the liquid droplets or solid particles may for example have a particle size in the range of about 0.5 to about 10 microns, and optionally from about 0.5 to about 5 microns.
  • the solid particles provide for controlled release through the use of a degradable polymer.
  • the solid particles can be obtained by processing the solid compound or a salt thereof, in any appropriate manner known in the art, such as by micronization.
  • the size of the solid particles or droplets can be from about 1 to about 2 microns.
  • commercial nebulizers are available to achieve this purpose.
  • the compounds can be administered via an aerosol suspension of respirable particles in a manner set forth in U.S. Pat. No. 5,628,984, the disclosure of which is incorporated herein by reference in its entirety.
  • compositions also are provided which provide a controlled release of a compound described herein, including through the use of a degradable polymer, as known in the art.
  • Example 1 Inhibitory Activity of Compound 1 in Combination with Eculizumab as Assessed Via a CAP-Mediated Hemolysis Assay with PNH Erythrocytes
  • the inhibitory activity of Compound 1 and the humanized monoclonal antibody Eculizumab was assessed via a CAP-mediated hemolysis assay with PNH erythrocytes from subjects (described in Example 3).
  • the CAP-mediated hemolysis assay with PNH erythrocytes was conducted two independent times and then analyzed by the method of Prichard and Shipman (described in Example 4).
  • the inhibition of CAP activity for each experiment is shown in Table 2.
  • the analytical results for each experiment, along with summary information, are shown in Table 3.
  • the three-dimensional surface-graphs used in the analysis method of Prichard and Shipman are shown in FIGS. 1A-1B .
  • Compound 1 and Eculizumab exhibited a strongly synergistic inhibition of CAP activity as indicated by a substantial synergy volume (306+57 ⁇ M ⁇ g/mL ⁇ % inhibition, Table 2) and by the distinct and consistent positive peaks observed on the surface graphs from both independent experiments ( FIGS. 1A-1B ).
  • Example 2 Inhibitory Activity of Compound 1 in Combination with Compstatin as Assessed Via a CAP-Mediated Hemolysis Assay with PNH Erythrocytes
  • the inhibitory activity of Compound 1 and the complement C3 inhibitor Compstatin was assessed via a CAP-mediated hemolysis assay with PNH erythrocytes from subjects (described in Example 3).
  • the CAP-mediated hemolysis assay with PNH erythrocytes was conducted two independent times and then analyzed by the method of Prichard and Shipman (described in Example 4) and by the method of Chou and Talalay (described in Example 5).
  • the inhibition of CAP activity for each experiment is shown in Table 4.
  • the analytical results for each experiment are shown in Table 5.
  • the three-dimensional surface-graphs used in the analysis method of Prichard and Shipman are shown in FIGS. 2A-2B .
  • Compound 1 and Compstatin showed a strongly synergistic inhibition of CAP activity as indicated by a substantial synergy volume (324+2 ⁇ M 2 ⁇ % inhibition, Table 4) and by the distinct and consistent positive peaks observed on the surface graphs from both independent experiments ( FIGS. 2A-2B ). No antagonistic interaction was observed.
  • the interaction was characterized as synergistic when analyzed by the method of Chou and Talalay.
  • Compound 1 and Compstatin showed synergistic interactions when assessed at the 50%, 75% and 90% inhibition level (Table 4). Specifically, the CI values determined at all three inhibition levels fell within the synergistic interval (between 0.7 and 0.85) at all three fixed combination ratios.
  • Compound 1 and Compstatin were prepared as 15 mM stocks in DMSO.
  • Eculizumab was obtained as a 10 mg/mL stock in buffered saline.
  • Complement-preserved normal human serum (NETS) from an individual donor of ABO blood group type AB (NHS-AB) was purchase from BioreclamationIVT (Westbury, N.Y.).
  • Gelatin veronal buffer (GVB), pH 7.3, without Ca ++ and Mg ++ ) (GVB 0 ) and 100 mM MgCl 2 +100 mM EGTA (MgEGTA) were obtained from Complement Technology Inc. (Tyler, Tex.).
  • GVB 0 ⁇ MgEGTA was prepared by mixing GVB 0 and 100 mM MgEGTA in a 9:1 ratio. PNH erythrocytes were used within five days of blood collection; before assay cells were collected by centrifugation at 800 ⁇ g and 4° C. for 3 minutes and resuspended in fresh cold GVB 0 ⁇ MgEGTA to a density of 5 ⁇ 108 cells/mL.
  • Compound 1 and Compstatin were prepared individually in seven-point two-fold dilution series at 50 ⁇ final assay concentration in dimethyl sulfoxide (DMSO) and Eculizumab was prepared in a seven-point two-fold dilution series at 25 ⁇ final assay concentration in GVB 0 ⁇ MgEGTA; an eighth sample was prepared for each test compound containing DMSO or GVB 0 ⁇ MgEGTA without compound.
  • DMSO dimethyl sulfoxide
  • the following controls were each included in quadruplicate for ACH-0141 with Eculizumab 1 ⁇ L DMSO+120 ⁇ L GVB0 ⁇ MgEGTA (representing background signal); 1 ⁇ L DMSO+100 ⁇ L GVB 0 ⁇ MgEGTA+20 ⁇ L PNH cells (no serum, representing 0% CAP-mediated lysis); 1 ⁇ L DMSO+76 ⁇ L GVB 0 ⁇ MgEGTA+24 ⁇ L NHS-AB+20 ⁇ L PNH cells (no compound, representing 100% CAP-mediated lysis); 1 ⁇ L DMSO+76 ⁇ L GVB 0 ⁇ MgEGTA+24 ⁇ L heat-inactivated NHS-AB+20 ⁇ L Er (heat inactivated serum, representing 0% CAP-mediated lysis and serum back ground control); and 1 ⁇ L DMSO+100 ⁇ L H 2 O+20 ⁇ L PNH cells (osmotic lysis, representing maximal lysis).
  • Compound 1 and Compstatin achieved complete inhibition at the high end of the combination's test concentration ranges, but Eculizumab achieved only 34% and 38% inhibition at its maximal test concentration of 400 ⁇ g/mL in two experiments.
  • Inhibition was analyzed by the method of Prichard and Shipman (Prichard, M. N. and C. Shipman, Jr. A Three-Dimensional Model to Analyze Drug-Drug Interactions. Antiviral Research 1990, 14: 181-205) Three-dimensional surface graphs of each experiment were generated and analyzed using an Excel spreadsheet program adapted from the MacSynergy II spreadsheet (University of Alabama, Birmingham, Ala.).
  • the X-axis and Y-axis of each surface graph represent the concentrations of the two test compounds, and the Z-axis represents the difference between measured inhibition and a theoretically determined additive inhibition.
  • compounds were considered slightly antagonistic for volumes between ⁇ 25 and ⁇ 50 ⁇ M 2 ⁇ % inhibition, moderately antagonistic for volumes between ⁇ 50 and ⁇ 100 ⁇ M 2 ⁇ % inhibition, and strongly antagonistic for volumes less than ⁇ 100 ⁇ M 2 ⁇ % inhibition.
  • Interactions were considered slightly synergistic for CI values between 0.85 and 0.9, moderately synergistic for CI values between 0.7 and 0.85; synergistic for CI values between 0.3 and 0.7, and strongly synergistic for CI values between 0.1 and 0.3. Interactions were considered slightly antagonistic for CI values between 1.1 and 1.2, moderately antagonistic for CI values between 1.2 and 1.45; antagonistic for CI values between 1.45 and 3.3, and strongly antagonistic for CI values between 3.3 and 10.
  • the inhibitory activity of Compound 1 against CAP activity in combination with the peptidic C3 inhibitor Compstatin was analyzed using the CAP-mediated hemolysis assay with rabbit erythrocytes. It was determined whether the combination was additive, synergistic, or antagonistic by two analytical methods: the three-dimensional surface-graphing method of Prichard and Shipman (described in Example 4) and the median-effect plot method of Chou and Talalay (described in Example 5).
  • the CAP-mediated hemolysis assay (described in Example 9) was conducted four independent times and then analyzed by the two methods.
  • the inhibition of CAP activity for each experiment is shown in Table 7 and the analytical results for each experiment are shown in Table 8.
  • the three-dimensional surface-graphs used in the analysis method of Prichard and Shipman are shown in FIGS. 3A-3D .
  • Compound 1 and Compstatin showed a strongly synergistic inhibition of CAP activity as indicated by a substantial synergy volume (149 ⁇ 125 ⁇ M2 ⁇ % inhibition, Table 8) and by the distinct and consistent positive peaks observed on the surface graphs from all four independent experiments ( FIGS. 3A-3D ).
  • the antagonism volumes in these four experiments also suggests a slightly antagonistic relationship ( ⁇ 27 ⁇ 22 ⁇ M2 ⁇ % inhibition, Table 8), although the dispersed and inconsistent appearance of the negative volumes across the four experiments might have been an experimental artifact.
  • the interaction was characterized as additive (synergistic to slightly antagonistic) when analyzed by the method of Chou and Talalay.
  • the analysis was conducted on three of the four experiments, with experiment 1 excluded from the average CI values for having too few data points in the prescribed concentration ranges.
  • the inhibitory activity of Compound 1 against CAP activity in combination with the monoclonal antibody inhibitor of complement C5 was analyzed using the CAP Wieslab assay (described in Example 10).
  • the CAP-mediated hemolysis assay could not be used because the antibody had previously shown insufficient activity in the hemolysis assay for use in combination experiments. It was determined whether the combination was additive, synergistic, or antagonistic by two analytical methods: the three-dimensional surface-graphing method of Prichard and Shipman (described in Example 4) and the median-effect plot method of Chou and Talalay (described in Example 5).
  • the CAP Wieslab assay (described in Example 10) was conducted three independent times and then analyzed by the two methods.
  • the inhibition of CAP activity for each experiment is shown in Table 9 and the analytical results for each experiment are shown in Table 10.
  • the three-dimensional surface-graphs used in the analysis method of Prichard and Shipman are shown in
  • FIGS. 4A-4C are views of FIGS. 4A-4C .
  • Compound 1 and anti-05 showed synergistic inhibition of CAP activity as indicated by synergy volume (81 ⁇ 51 ⁇ M ⁇ g/mL ⁇ % inhibition, Table 10) and by the distinct positive peak evident on the surface graphs from the three experiments ( FIGS. 4A-4C ). No antagonistic interaction was observed.
  • the interaction was characterized as additive (synergistic to additive) when characterized by the method of Chou and Talaly.
  • the inhibitory activity of Compound 1 against CAP activity in combination with the broad-spectrum complement inhibitor FUT-175 was analyzed using the CAP-mediated hemolysis assay. It was determined whether the combination was additive, synergistic, or antagonistic by two analytical methods: the three-dimensional surface-graphing method of Prichard and Shipman (described in Example 4) and the median-effect plot method of Chou and Talalay (described in Example 5).
  • the CAP-mediated hemolysis assay (described in Example 9) was conducted three independent times and then analyzed by the two analytical methods.
  • the inhibition of CAP activity for each experiment is shown in Table 11 and the analytical results for each experiment are shown in Table 12.
  • the three-dimensional surface-graphs used in the analysis method of Prichard and Shipman are shown in FIGS. 5A-5C .
  • Compound 1 and FUT-175 showed synergistic inhibition of CAP activity as indicated by synergy volume (78 ⁇ 40 ⁇ M2 ⁇ % inhibition, Table 12) and by the distinct positive peak evident on the surface graphs from the three experiments ( FIGS. 5A-5C ).
  • a slightly antagonistic interaction was also suggested by the observed antagonism volume ( ⁇ 47 ⁇ 22 ⁇ M 2 ⁇ % inhibition, Table 12), although without committing to any one theory, the dispersed and inconsistent appearance might have been an experimental artifact.
  • Compound 1 was fully characterized by 1 H-NMR, HPLC, and mass spectrometry.
  • Compstatin was obtained from Tocris Bioscience (Bristol, UK).
  • FUT-175 (nafamostat) was obtained from Calbiochem EMD Millipore (Billerica, Mass.).
  • Compound 1, FUT-175, and Compstatin were prepared as 10 mM stocks in DMSO.
  • Anti-C5 murine monoclonal antibody to human C5, isotype IgG1K, product No. A217 from Quidel, San Diego, Calif.
  • GVB Gelatin veronal buffer
  • NETS normal human serum
  • Er rabbit erythrocytes
  • GVB 0 ⁇ MgEGTA was prepared by mixing GVB 0 and 100 mM MgEGTA in a 9:1 ratio. Er cells were used within two weeks of purchase; before each assay cells were collected by centrifugation at 800 ⁇ g and 4° C. for 3 minutes and the buffer was replaced with equal volume fresh cold GVB 0 ⁇ MgEGTA.
  • Compound 1 and a second test compound were prepared individually in seven-point two-fold dilution series at 100 ⁇ final assay concentration in DMSO, with an eighth sample for each test compound containing DMSO alone. Each of the 64 possible combinations of compounds at varying concentrations was tested in duplicate or triplicate wells. 1.2 ⁇ L each of Compound 1 and the second test Compound 1n the appropriate dilutions were added to wells of polypropylene V-bottom microtiter plates. 50 ⁇ L GVB 0 ⁇ MgEGTA was added to each well, followed by 50 ⁇ L 20% NHS in GVB 0 ⁇ MgEGTA. The plates were sealed, mixed on a microtiter plate shaker, and incubated at 37° C. for 15 minutes.
  • the complement system alternative pathway Wieslab kit (COMPL AP330) was purchased from Euro Diagnostica (Malmo, Sweden).
  • the Wieslab assay for CAP-mediated TCC production was conducted as described by the manufacturer.
  • Compound 1 was prepared individually in a seven-point two-fold dilution series at 100 ⁇ final assay concentration in
  • Anti-C5 was prepared in a seven-point two-fold dilution series at 22 ⁇ final assay concentration in the Diluent AP reagent provided with the Wieslab kit. Each of the 64 possible combinations of inhibitors at varying concentrations was tested in duplicate wells. 1.25 Compound 1 at the appropriate dilutions was added to microtiter wells. 125 ⁇ L NHS diluted 1/18 ⁇ in Diluent AP was added to each well, and then 6 ⁇ L anti-C5 at the appropriate dilutions was added and mixed. 100 ⁇ L was transferred to wells of the CAP Wieslab plate. Positive and negative control wells were included in quadruplicate with no inhibitor and no serum respectively.
  • Plates were incubated for 60 minutes at 37° C. Wells were emptied, washed 3 ⁇ with washing solution, and incubated with 100 ⁇ L alkaline phosphatase-labelled detection antibody for 30 minutes at room temperature. Wells were emptied, washed 3 ⁇ with washing solution, and incubated with 100 ⁇ L alkaline phosphatase substrate for 30 minutes at room temperature. A 405 in each well was measured in a Molecular Devices Spectramax Plus plate reader.
  • Rabbit erythrocytes, C5-depleted normal human serum (C 5 -Dpl NHS), gelatin veronal buffer (GVB) without Ca ++ and Mg ++ (GVB 0 ), 100 mM MgCl 2 +100 mM EGTA (MgEGTA) were obtained from Complement Technology Inc. (Tyler, Tex.).
  • GVB 0 ⁇ MgEGTA was prepared by mixing GVB 0 and 100 mM MgEGTA in a 9:1 ratio.
  • FITC-conjugated anti-C3c antibody catalog# ab4212
  • Alexa Fluor® 647-conjugated anti human CD59 antibody catalog#: ab187769 were purchased from Abcam (Cambridge, Mass.).
  • reaction were performed in volume of 100 ⁇ L containing C5-depleted normal human serum (C5-Dpl NHS) at a final concentration of 20% and rabbit erythrocytes at a final density of 5 ⁇ 10 7 /mL in GVB 0 ⁇ MgEGTA buffer in the absence or presence of Compound 1 at concentrations ranging from 0.0003 to 10 ⁇ M. Reactions were incubated at 37° C. for 15 minutes, the reactions were quenched by addition of EDTA at a final concentration of 20 mM.
  • C5-Dpl NHS C5-depleted normal human serum
  • erythrocytes were stained with a FITC-conjugated anti-C3c antibody at a dilution of 1:200 and C3 fragment deposition on the surface of rabbit erythrocytes was assessed by flow cytometry with BD Accuri C6 cytometer (BD Biosciences, San Jose, Calif.). Forward and side scatter parameters were used to gate intact erythrocytes. Controls included cells labeled with FITC-conjugated antibody isotype control.
  • IC 50 values from each experiment were determined by curve-fitting of experimental data (the % C3 fragment-positive cells at increasing concentrations of inhibitor) to the four-parameter sigmoidal dose-response equation using non-linear regression analysis (Prism Software, GraphPad, La Jolla, Calif.).
  • Normal human type 0 red blood cells were purchased from BioreclamationIVT (Westbury, N.Y.). 2-amino-ethylisothiouronium bromide (AET) was purchased from Sigma Aldrich.
  • C5-depleted normal human serum C5-Dpl NHS
  • gelatin veronal buffer GVB
  • GVB 0 gelatin veronal buffer
  • 100 mM MgCl 2 +100 mM EGTA MgEGTA
  • GVB 0 ⁇ MgEGTA was prepared by mixing GVB 0 and 100 mM MgEGTA in a 9:1 ratio.
  • FITC-conjugated anti-C3c antibody catalog# ab4212
  • Alexa Fluor® 647-conjugated anti human CD59 antibody catalog#: ab187769 were purchased from Abcam (Cambridge, Mass.).
  • GVB 0 ⁇ MgEGTA buffer pH 6.4
  • Cells were stained with a FITC-conjugated anti-C3c antibody and Alexa Fluor® 647-conjugated anti human CD59 antibody at a dilution of 1:200.
  • C3 fragment deposition on the surface of the erythrocytes was assessed by flow cytometry with BD Accuri C6 cytometer (BD Biosciences, San Jose, Calif.). Forward and side scatter parameters were used to gate intact erythrocytes.
  • Controls included cells stained with FITC- and Alexa Fluor® 647-conjugated isotype controls.
  • IC 50 values from each experiment were determined by curve-fitting of experimental data (the % C3 fragment-positive cells at increasing concentrations of inhibitor) to the four-parameter sigmoidal dose-response equation using non-linear regression analysis (Prism Software, GraphPad, La Jolla, Calif.).
  • FIGS. 7A-7L Representative dot plots for the inhibitory effect of Compound 1 and compstatin on C 3 fragment deposition are shown in FIGS. 7A-7L , and the dose-response curves for the two inhibitors are shown FIG. 7M .
  • FIGS. 7A-7L Representative dot plots for the inhibitory effect of Compound 1 and compstatin on C 3 fragment deposition are shown in FIGS. 7A-7L , and the dose-response curves for the two inhibitors are shown FIG. 7M .
  • FIGS. 7A-7L Representative dot plots for the inhibitory effect of Compound 1 and compstatin on C 3 fragment deposition are shown in FIGS. 7A-7L , and the dose-response curves for the two inhibitors are shown FIG. 7M .
  • Serum-mediated C3 fragment deposition on erythrocytes from PNH subject A was assessed with Compound 1 alone and in combination with eculizumab.
  • Physiological conditions were defined as 5 min pre-incubation of serum with inhibitor, 72% ABO blood group-compatible serum, 5 ⁇ 107/mL erythrocytes from PNH subject A, GVB++ buffer, 37° C. for 1 hour, EDTA termination.
  • Hemolysis was assessed from A405 of supernatants following centrifugation.
  • C3 fragment deposition on intact and fragmented cells was assessed by flow cytometry using FITC-conjugated anti-C3c (Abcam Ab4212, 1:200), PE-conjugated anti-CD47 (R&D Systems FAB4670P, 1:50), and APC-conjugated anti-CD59 (Abcam Ab187769, 1:200 dilution) following dilution of reaction mixtures in FC buffer (PBS+15 mM EDTA, 1% BSA). After incubation at room temperature for 30 min, samples were diluted to final 1:20 in FC buffer and examined by flow cytometry (BD Accuri C6) with a Fsc-H>20,000 threshold.
  • FC buffer PBS+15 mM EDTA, 1% BSA
  • Intact and fragmented PNH erythrocytes were identified by anti-CD47 (positive) and anti-CD59 (negative) staining; Intact and fragmented cells were distinguished from each other by size (FSC-A); C3 fragment deposition was assessed by anti-C3c staining.
  • eculizumab therapy consists of:
  • Patient Body Weight Induction Maintenance 40 kg and over 900 mg weekly ⁇ 4 1200 mg at week 5; doses then 1200 mg every 2 weeks 30 kg to less than 40 kg 600 mg weekly ⁇ 2 900 mg at week 3; doses then 900 mg every 2 weeks 20 kg to less than 30 kg 600 mg weekly ⁇ 2 600 mg at week 3; doses then 600 mg every 2 weeks 10 kg to less than 20 kg 600 mg weekly ⁇ 1 300 mg at week 3; dose then 300 mg every 2 weeks 5 kg to less than 10 kg 300 mg weekly ⁇ 1 300 mg at week 2; dose then 300 mg every 3 weeks Eculizumab is administered by intravenous infusion over 35 minutes in adults and 1 to 4 hours in pediatric patients via gravity feed, a syringe-type pump, or an infusion pump.
  • the starting dose of compound 1 is based upon group assignment.
  • the Group 1 dose is 100 mg three times daily (TID).
  • the Group 2 dose is 150 mg TID.
  • the Group 3 dose is 200 mg TID.
  • the Group 4 dose will receive the optimal dose determined from Groups 1-3.
  • Compound 1 is administered orally three times daily (TID) over a period of 24 weeks while patients continue to receive eculizumab at their usual dose and schedule described above. Compound 1 is dosed in the morning, a second dose approximately 8 hours later, and a third dose approximately 8 hours after the second dose. All doses are taken approximately 15-30 minutes after completion of a meal or snack.
  • TID three times daily
  • This study will include up to 12 subjects who will receive 24 weeks of daily oral treatment with Compound 1 plus intravenous (IV) eculizumab administered at the subject's usual dose and schedule. This will be followed by a long-term extension phase.
  • IV intravenous
  • the first three groups will include 2 subjects per group to determine an optimal Compound 1 dose for the remaining 6 subjects in the fourth group.
  • Subjects will return to the clinic for safety, PK, and other assessments at Week1, Week 2, Week 4, Week 8, and Week 12, and then every 4 weeks until Week 24.
  • the study population will include adult PNH subjects with RBC-transfusion-dependent anemia (defined as having received at least one RBC transfusion within 12 weeks prior to screening) and who are receiving a stable dose of eculizumab (have been receiving eculizumab at approved or higher doses for at least 24 weeks prior to entry without change in dose or schedule for at least 12 weeks).
  • LDH lactate dehydrogenase
  • Type III PNH red blood cells
  • C3 Fragment Deposition percentage C3 Fragment Deposition percentage
  • Lactate dehydrogenase is a pharmacodynamic marker that is measured from blood drawn on Day 1, Week 1, Week 2, and Week 4 ( FIGS. 13A & 13B and Table 15). High levels of LDH in the blood can be an indication of hemolysis.
  • Free hemoglobin is a pharmacodynamic marker that is measured from blood drawn on Day 1, Week 1, Week 2, and Week 4 ( FIGS. 14A & 14B and Table 16). Low levels of hemoglobin is a sign of hemolytic anemia.
  • a reticulocyte count is a pharmacodynamic marker that is measured from blood drawn on Day 1, Week 1, Week 2, and Week 4 ( FIGS. 15A & 15B and Table 17).
  • a reticulocyte count measures the number of immature red blood cells in a blood sample. People who have PNH may have elevated reticulocyte counts because their bone marrow is producing a lot of new red blood cells.
  • PNH Type III red blood cells is a pharmacodynamic marker that is measured by flow cytometry, which provides information on cell size, shape, and percentage of a type of cell. This assay determines whether CD55 and CD59 are missing from the surface of red blood cells. These proteins help protect normal cells from hemolysis. PNH Type III cells are extremely sensitive to the complement system and hemolysis. PNH Type III cell percentage is measured from plasma drawn on Day 1, Week 2, and Week 4 ( FIGS. 16A & 16B and Table 18).
  • Measurement of C3 fragment deposition percentage is a pharmacodynamic marker that is measured by flow cytometry of subject plasma samples collected on Day 1, Week 2, and Week 4 ( FIGS. 17A & 17B and Table 19). Uncontrolled C3 activation due to the absence of CD55 on red blood cells may result in opsonization of red blood cells, leading to clinically meaningful extravascular hemolysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US16/053,716 2017-08-02 2018-08-02 Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria Abandoned US20190038623A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/053,716 US20190038623A1 (en) 2017-08-02 2018-08-02 Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
US16/700,910 US20200101071A1 (en) 2017-08-02 2019-12-02 Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762540451P 2017-08-02 2017-08-02
US201762593669P 2017-12-01 2017-12-01
US16/053,716 US20190038623A1 (en) 2017-08-02 2018-08-02 Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/700,910 Continuation US20200101071A1 (en) 2017-08-02 2019-12-02 Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria

Publications (1)

Publication Number Publication Date
US20190038623A1 true US20190038623A1 (en) 2019-02-07

Family

ID=65231296

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/053,716 Abandoned US20190038623A1 (en) 2017-08-02 2018-08-02 Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
US16/700,910 Pending US20200101071A1 (en) 2017-08-02 2019-12-02 Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/700,910 Pending US20200101071A1 (en) 2017-08-02 2019-12-02 Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria

Country Status (4)

Country Link
US (2) US20190038623A1 (zh)
EP (1) EP3661493A4 (zh)
CN (1) CN111163767A (zh)
WO (1) WO2019028284A1 (zh)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020041301A1 (en) * 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
US10906887B2 (en) 2015-08-26 2021-02-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US10919884B2 (en) 2015-08-26 2021-02-16 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
US11053253B2 (en) 2017-03-01 2021-07-06 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
US11084800B2 (en) 2017-03-01 2021-08-10 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2021168320A1 (en) * 2020-02-20 2021-08-26 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
US11407738B2 (en) 2015-08-26 2022-08-09 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US11447465B2 (en) 2017-03-01 2022-09-20 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for treatment of medical disorders
US11807627B2 (en) 2018-09-25 2023-11-07 Achillon Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3898617A4 (en) * 2018-12-17 2022-08-17 Achillion Pharmaceuticals, Inc. TARGETED DOSING FOR THE TREATMENT OF COMPLEMENT-MEDIED DISORDERS
WO2024008121A1 (zh) * 2022-07-06 2024-01-11 南京明德新药研发有限公司 二氟取代的氮杂双环化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130029912A1 (en) * 2009-11-05 2013-01-31 Holers V Michael Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
WO2015130838A1 (en) * 2014-02-25 2015-09-03 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
US10138225B2 (en) * 2015-08-26 2018-11-27 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of medical disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3124029A1 (en) * 2006-03-15 2017-02-01 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
AR106018A1 (es) * 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035361A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130029912A1 (en) * 2009-11-05 2013-01-31 Holers V Michael Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
WO2015130838A1 (en) * 2014-02-25 2015-09-03 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
US9796741B2 (en) * 2014-02-25 2017-10-24 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
US10138225B2 (en) * 2015-08-26 2018-11-27 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of medical disorders

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407738B2 (en) 2015-08-26 2022-08-09 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US10906887B2 (en) 2015-08-26 2021-02-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US10919884B2 (en) 2015-08-26 2021-02-16 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
US11926617B2 (en) 2015-08-26 2024-03-12 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US11649223B2 (en) 2015-08-26 2023-05-16 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US11649229B2 (en) 2015-08-26 2023-05-16 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
US11718626B2 (en) 2017-03-01 2023-08-08 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
US11447465B2 (en) 2017-03-01 2022-09-20 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for treatment of medical disorders
US11084800B2 (en) 2017-03-01 2021-08-10 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US11708351B2 (en) 2017-03-01 2023-07-25 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US11053253B2 (en) 2017-03-01 2021-07-06 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
US12006307B2 (en) 2017-03-01 2024-06-11 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2020041301A1 (en) * 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
US11807627B2 (en) 2018-09-25 2023-11-07 Achillon Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
CN115362162A (zh) * 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
WO2021168320A1 (en) * 2020-02-20 2021-08-26 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders

Also Published As

Publication number Publication date
US20200101071A1 (en) 2020-04-02
WO2019028284A1 (en) 2019-02-07
EP3661493A4 (en) 2021-04-14
CN111163767A (zh) 2020-05-15
EP3661493A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
US20200101071A1 (en) Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
US20220081391A1 (en) Methods
US20220079943A1 (en) Targeted dosing for the treatment of complement mediated disorders
TWI624258B (zh) 治療法布裡病之給藥方案
EP2844279B1 (en) Dosing regimens for the treatment of pompe disease
US11723949B2 (en) Modulators of complement activity
EP3389692B1 (en) Modulators of complement activity
JP2010525084A (ja) 薬理シャペロンを用いたリソソーム蓄積症治療のための投薬計画
JP2020203886A (ja) 腎機能障害を有するファブリー患者の治療方法
MX2013012939A (es) Inhibidores de csf-1r para el tratamiento de tumores de cerebro.
US11180560B2 (en) Compositions and methods to treat solid tumors
US20210113560A1 (en) Method of treating fibrotic disease
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
US20210215714A1 (en) Complement alternative pathway-associated nephropathy biomarkers
US20230136297A1 (en) Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
CN103989682B (zh) 使用centhaquin的治疗法
WO2012151541A1 (en) Csf-1r inhibitors for treatment of brain tumors
JP2022518733A (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
JPWO2014065341A1 (ja) 筋萎縮性側索硬化症治療剤
US11234942B2 (en) Composition and method for inhibiting platelet aggregation
US20180215811A1 (en) Antibody binding agents that bind acinetobactor and uses thereof
US20220387435A1 (en) Use of multi-target protein kinase inhibitor
JP2017109987A (ja) ＥｒｂＢ４＋炎症性マクロファージによって媒介される疾患の治療方法
US20190314379A1 (en) Methods of using cannabinoid cb2 receptor agonist compositions to suppress and prevent opioid tolerance and withdrawal in a subject
US20220362357A1 (en) Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: ACHILLION PHARMACEUTICALS, INC., CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUANG, MINGJUN;PODOS, STEVEN D.;PATEL, DHARABEN;SIGNING DATES FROM 20171113 TO 20171128;REEL/FRAME:047471/0335

Owner name: ACHILLION PHARMACEUTICALS, INC., CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUANG, MINGJUN;PODOS, STEVEN D.;PATEL, DHARABEN;REEL/FRAME:047471/0328

Effective date: 20180111

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION